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Researchers from NUI Galway’s 
Centre for Pain Research recent-
ly received prestigious prizes for 
their research at the Annual Sci-
entific Meeting of the Irish Pain 
Society 2019, continuing an 
impressive track record of suc-
cess in these competitions. Re-
searchers from the Centre won 
prizes in every research cat-
egory at the event. Ms Orlaith 
Mannion won Best Presenta-
tion at the Irish Pain Research 
Network short oral data blitz for 
her short presentation demon-
strating that drugs which boost 
levels of the body’s own mar-
ijuana-like cannabinoids have 
potential for effective treatment 
of postoperative pain following 
groin hernia repair. Ms Rachel 
Humphrey won the Irish Pain 
Society Preclinical Research 
Medal for her poster demon-
strating that alterations in pain 
processing may be a feature 
of autism spectrum disorder 
symptomatology, and pinpoint-
ing brain regions that could be 
implicated. Ms Mehnaz Ferdousi won second prize in the Preclinical Poster category for her 
Science Foundation Ireland-funded research on the effects of novel opioid drugs on pain, 
anxiety and depression-related behaviour. Ms Monika Pilch won the Irish Pain Society Clini-
cal Research Medal for Best Clinical Poster on how perspective-taking influences what we 
pay attention to when evaluating facial expressions of pain. Ms Nessa Sweeney won second 
prize in the clinical poster category for her work examining the experience of young Irish 
mentors supporting adolescents with juvenile idiopathic arthritis.
ICGP green-lights pharmacist prescribing model 
A “highly-trained pharmacist pre-
scriber” under the governance 
and supervision of a managing GP 
would be “an additional valuable 
resource in the community”, the 
ICGP has stated.
Responding to questions on the 
future role of community pharma-
cists in Ireland, a College spokes-
person said: “If care is shared with 
GPs and is guided and directed 
by the GP, then a pharmacist pre-
scriber would add to the com-
munity support team for patients. 
Pharmacist prescribers would re-
quire extra training and thorough 
and comprehensive guidelines 
and protocols in order to ensure 
patient safety and wellbeing.”
The College also issued a posi-
tive opinion on a potential minor 
ailments scheme in pharmacy, 
subject to certain conditions be-
ing met, which is a departure from 
a previous standpoint communi-
cated in 2016.
“Community pharmacists 
already treat several minor ail-
ments, such as minor coughs and 
respiratory infections and some 
skin infections, among other ail-
ments, and this of course helps 
to reduce pressure on the hos-
pital emergency services and on 
other parts of the health service,” 
stated a College spokesperson last 
month. 
“A community pharmacist-
provided minor ailments scheme 
would require clear guidelines, 
protocols and governance struc-
tures, as well as training of phar-
macy support staff.” 
See feature, p16 ▸
PHARMACIST PRESCRIBING CLEAN SWEEP OF PRIZES FOR CENTRE FOR PAIN RESEARCH AT NUIG
SAFETY INCIDENTS
Department of Health working on legislation for mandatory open disclosure
The recent Irish Medication Safety 
Network (IMSN) Annual Confer-
ence 2019, held in the RCSI, heard 
from Ms Marita Kinsella, Director 
of the National Patient Safety Of-
fice at the Department of Health, 
who told the attendees that the 
Department is currently working 
on the preparation of a bill that 
will require mandatory open dis-
closure of serious patient safety 
incidents and events.
Ms Kinsella told the conference, 
which was held under the theme 
‘Medication Without Harm: Re-
sponding to the Challenge’: “As a 
health service, openness and hon-
esty with patients must be at the 
heart of everything we do. Open 
disclosure must happen in the 
right way and in all circumstances 
— patients have to be informed. 
“We have seen all too clearly 
arising from a number of serious 
patient safety incidents over re-
cent years the impact that failure 
of open disclosure can have on pa-
tients. It’s important that we’re all 
committed to learning from these 
events and embedding a culture of 
ensuring that patients are treated 
in a way that they would most 
like to be treated when things go 
wrong, that they perceive a sin-
cere and genuine apology, and to 
be sure that what has happened to 
them will not happen to anybody 
else,” she continued.
“We need to ensure that the 
culture of trust and confidence 
between patients and clinicians 
prevails. Within the team at the 
National Patient Safety Office, we 
have been working on a new pa-
tient safety bill, which will focus 
on mandatory open disclosure 
of the most serious patient safety 
incidents. This will ensure that pa-
tients and their families affected 
by a serious incident will be as-
sured of receiving appropriate and 
timely information in relation to 
an unintended or anticipated seri-
ous event that may have occurred 
in relation to their care.”
Ms Kinsella added that the 
mandatory disclosure bill will also 
require notification of the most 
serious patient safety events and 
incidents to HIQA and the Men-
tal Health Commission, as ap-
propriate, to ensure system-wide 
improvements. However, she de-
scribed the legislation as a “blunt 
tool” to embed a culture of open-
ness and transparency in cases of 
serious incidents. “Ensuring that 
patients and their families are 
treated honestly and openly when 
things go wrong also requires per-
sonal commitment from all of us 
who work in the health service,” 
she added. 
See conference coverage on p10-15
Ms Marita Kinsella
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New scheme initiated to help pharmacists launch their own business
Irish pharmacy group totalhealth 
has launched a new scheme, which 
it says will “revitalise the local Irish 
pharmacy industry”. The ‘Phar-
macy Assistance Purchase Scheme 
(PAPS)’ aims to facilitate Irish phar-
macists with the launch of their 
own business. The purpose of the 
scheme is to remove some of the 
barriers faced by pharmacists who 
wish to become pharmacy owners 
by providing financial assistance 
and business support.
The landscape for independent 
pharmacies is challenging and for 
pharmacists who wish to establish 
their own local operation and serve 
their local community, the task is 
becoming more difficult, said total-
health. The scheme aims to support 
aspiring pharmacy owners through 
the PAPS initiative by assisting fi-
nancially with the launch of the 
business, alongside an established 
Irish financial institution.
The scheme will also see the 
pharmacies open under the to-
talhealth symbol group, which 
currently has 80 pharmacies na-
tionwide, and the PAPS initiative is 
part-funded by totalhealth member 
investors and will provide financial 
assistance to those wishing to pur-
chase a pharmacy.
Mr John Arnold, Managing Di-
rector of totalhealth Pharmacy, 
commented: “We want to facilitate 
pharmacists with the PAPS scheme 
in achieving their goal of owning 
and operating their own pharmacy. 
I have seen the struggles faced by 
both current and potential pharma-
cy owners. Raising capital is a ma-
jor barrier to entry, with financial 
institutions requiring a significant 
percentage of the purchase price 
up-front. Potential owners are also 
aware of the difficulties of running 
a pharmacy; operational costs can 
be daunting. By buying a pharmacy 
within an established symbol group 
such as totalhealth, owners have 
all the benefits of working with an 
overarching, recognisable brand, as 
well as an alleviation of the financial 
constraints, giving aspiring phar-
macy owners a fair start on their 
business journey”.
PAPS Chairperson Mr Rory 
O’Donnell added: “It’s almost as 
difficult for a pharmacist to sell 
their business as it is for someone to 
buy it. With this new scheme, we’re 
helping at both ends of the pro-
cess, as well as offering our existing 
members a unique investment op-
portunity. Pharmacy owners wish-
ing to retire or sell their businesses 
can be confident that their patients 
and customers will continue to re-
ceive a high standard of service and 
care when they do.” 
The board of PAPS is advised by 
Fitzgerald Power Chartered Ac-
countants and AMOSS Solicitors. 
IPU welcomes Minister’s commitment to pharmacy contract talks in 2020 
The Irish Pharmacy Union (IPU) 
welcomed what it called the “sen-
sible” decision by the Minister for 
Health Simon Harris not to pro-
ceed with the proposed cuts in 
fees to pharmacies and, instead, 
to recommit to early talks on a 
new pharmacy contract and in-
vestment in pharmacy services.   
Deep cuts to pharmacy fees 
were proposed by the Depart-
ment of Health in October 2019 
and, following a concerted ef-
fort by pharmacists to push back 
against these further fee cuts, 
Minister Harris met with the IPU 
late last year and announced his 
decision not to introduce the 
cuts, but to leave fees as they are 
and to start contract talks early in 
the New Year. 
Speaking after the meeting, 
IPU Secretary General Mr Dar-
ragh O’Loughlin said: “While this 
reprieve is welcome, a significant 
increase in resources is urgently 
needed to meet the ever-increas-
ing costs of providing the existing 
service, to ensure the viability of 
community pharmacy and to al-
low pharmacists to deliver on 
their commitment to ongoing 
service development and reform, 
which will have significant ben-
efits for patients and the public.”
Mr O’Loughlin continued: 
“When the proposed cuts were 
announced in October, Ireland’s 
2,300 community pharmacists 
were left deeply shocked and con-
cerned and warned that these un-
fair and unjustifiable cuts would 
hit rural, disadvantaged and iso-
lated pharmacies hardest. Any 
funding cuts would also go com-
pletely against the Government’s 
Sláintecare strategy, which aims 
to keep health services in the local 
community.
“We are pleased that Minister 
Harris kept the promise he made 
at the National Pharmacy Confer-
ence in May this year, when he 
acknowledged the previous cuts 
to pharmacists’ incomes that had 
been imposed during the finan-
cial crisis and the resulting finan-
cial pain felt by pharmacists and 
stated the Government’s inten-
tion to unwind those cuts. He also 
committed to starting talks on a 
new pharmacy contract.
“New contract talks will also 
include discussions on an ex-
pansion of healthcare services in 
pharmacy,” Mr O’Loughlin com-
mented. “As we continue into the 
winter months and a rising trol-
ley count, this will deliver real 
benefits for patients and will take 
pressure off the rest of the health 
system and in particular over-
stretched accident and emergen-
cy departments and GP clinics. 
We look forward to working with 
Minister Harris and his officials in 
the New Year, and ensuring Irish 
patients are able to fully benefit 
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Ahead of World Aids Day 2019, 
research was published which 
showed one-in-five people are 
unaware of any HIV prevention 
methods. Specifically, 87 per cent 
of people had never heard of pre-
exposure prophylaxis (PrEP), yet 
36 per cent of people admitted 
that they would consider taking it. 
The research was conducted 
with Irish adults over 18 years of 
age, with a national average sam-
ple size of 969 people. 
Researchers examined several 
areas relating to HIV and PrEP, 
including the general public’s 
understanding of HIV and anti-
HIV drug PrEP, the role of HIV 
and STI clinics, and the aware-
ness and use of HIV prevention 
methods.
The research followed the 
Government’s recent announce-
ment of a new PrEP public ac-
cess programme, which began 
on 4 November 2019.
The survey found that 70 
per cent of people believed 
PrEP should be available free 
of charge. A formal PrEP pro-
gramme, as previously recom-
mended by the Health Infor-
mation and Quality Authority, 
would allow for a safe, effective 
and cost-saving environment.
PrEP, a HIV prevention 
medication, has been shown, 
in conjunction with safe sex 
practices, to significantly re-
duce the risk of HIV infection 
through sex, particularly for 
those deemed at risk, such 
as gay and bisexual men and 
transgender women, but also 
for heterosexual men and 
women.
The research was conduct-
ed by Core Research on behalf 





One-in-five people unaware of HIV prevention methods
KEY FINDINGS FROM THE 
RESEARCH INCLUDE:
65%
of Irish adults still believe 
that HIV is a sensitive subject.
93 per cent of people think 
there needs to be more infor-
mation on  HIV in Ireland.
79%
of people say that the first thing 
they would do if they found out they 
had HIV would be to visit a HIV clinic.
70%
of people feel that the risk of 
HIV is not taken into consideration 
before engaging in sexual activity.
One-in-five
are unaware of any HIV prevention 
methods but of those who did know, 
only 2 per cent mentioned PrEP.
87%
of people had never heard of PrEP, 
but 36 per cent of people admitted 
that they would consider taking it.
Seven-in-10
people believe PrEP should 
be available free of charge.
High Court rules in favour of Clonmel Healthcare on 
cholesterol-lowering therapy
Irish pharmaceutical company Clonmel Healthcare recently won a High 
Court case against Merck Sharp and Dohme (MSD) in a counter-claim 
over patent rights for the cholesterol-lowering drug Ezetimibe/Simv-
astatin. Previously, MSD took legal action against Clonmel Healthcare, 
claiming that Clonmel had breached MSD’s supplementary protection 
certificate (SPC) for Inegy, a drug produced by MSD. However, Clonmel 
Healthcare lodged a counter-claim against MSD, stating that the combi-
nation of Ezetimibe and Simvastatin was in fact unprotected by patent 
and that the MSD SPC was in breach of a 2009 EU SPC regulation.
Further, Clonmel Healthcare maintained that only Ezetimibe was pro-
tected and because the combination of Ezetimibe and Simvastatin was 
previously authorised, MSD’s 2005 SPC was not valid.  In the High Court, 
Mr Justice McDonald ruled that the compound combination is not pro-
tected by patent and “there is nothing in the evidence or in the materi-
als before the court to explain how the combination can be said to be an 
invention in itself”. As a result, he said the combination of compounds is 
not protected within Article 3(a) of the 2009 SPC and the certificate must 
be revoked. Mr Justice McDonald also stated that there was no legal basis 
for him to refer the case on to the EU’s Court of Justice.
Pharmacists highlighted in new OECD report
A report recently published by the Organisation for Economic Cooperation 
and Development (OECD), titled Health at a Glance 2019, has demonstrated 
how the health status and health-seeking behaviours of citizens across coun-
tries currently differ. Using 80 different indicators, it aimed to compare ac-
cess to and quality of healthcare in OECD countries. 
A chapter on pharmacists and pharmacies says that between 2000 and 
2017, the density of practising pharmacists increased on average by 33 per 
cent in OECD countries, to 83 pharmacists per 100,000 inhabitants. The 
highest density is in Japan (181 pharmacists per 100,000 people), and the 
lowest in the Netherlands (21 per 100,000). Community pharmacists’ role 
is changing, according to the report, as they increasingly provide care other 
than dispensing medicines to patients.
“The number of pharmacists per capita increased in all OECD countries 
for which time series are available,” according to the report. “Pharmacist 
density increased most rapidly in Japan, Portugal and Slovenia. In Japan, 
increased numbers of pharmacists are largely attributable to the govern-
ment’s efforts to more clearly separate drug prescribing by doctors from 
drug dispensing by pharmacists (the ‘Bungyo’ system).” The report goes on 
to state: “The role of the community pharmacist has changed over recent 
years. Although their main role is to dispense medications, pharmacists are 
increasingly providing direct care to patients (ie, flu vaccinations in Australia, 
Ireland and New Zealand; medicine adherence support in Australia, Japan, 
New Zealand and the United Kingdom), both in community pharmacies 
and as part of integrated health care provider teams.”
PrEP (Pre-Exposure 
Prophylaxis) can 
protect against HIV 
and makes sex safer 
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New research published finds 1 in 5 people are unaware of any HIV prevention methods.
A survey conducted in September 2019 by Core Research on behalf of Teva Pharmaceuticals Ireland examined several areas 
relating to HIV and PrEP including the general public’s understanding of HIV and the anti-HIV drug PrEP, the role of HIV and STI 
clinics, and the awareness and use of HIV prevention methods. The research was conducted with Irish adults over 18 years of age, 
with a national average sample size of 969 people. 
 
 
65% of Irish adults still believe that
HIV is a sensitive subject, yet 93% of 
people think there needs to be more 
information on HIV in Ireland
70% feel that the risk of HIV is not 
taken into consideration before 
engaging in sexual activity
87% of people had never heard of 
PrEP, but 36% of people admitted 
that they will consider taking it
79% of people say the first thing they 
would do if they found out they had 
HIV would be to visit a HIV clinic
20% are unaware of any 
HIV prevention methods
70% believe PrEP should 
be available free of charge
For more information visit PrEPLOVELIFE.ie
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Breast milk could help prevent heart disease caused by premature birth — RCSI study 
Early use of breast milk could play a 
vital role in preventing heart disease 
in prematurely-born infants, ac-
cording to a paper led by researchers 
at the RCSI and the Rotunda Hospi-
tal, Dublin.
One of the long-term health com-
plications that young adults born 
prematurely may have is unique 
heart characteristics. These can in-
clude smaller heart chambers, rela-
tively higher blood pressure, and a 
disproportionate increase in muscle 
mass in the heart. 
One study cited in the article 
looked at 30 preterm-born adults 
who were assigned to receive exclu-
sive human milk and 16 preterm-
born adults who were assigned to 
receive an exclusive formula-based 
diet during their hospital stay at 
birth. They then underwent detailed 
cardiovascular assessment between 
23 and 28 years of age, including an 
MRI of their hearts. As expected, all 
of the hearts of those born prema-
turely had smaller chambers than 
the hearts in people who were not 
born prematurely. 
However, the study showed that 
the smaller heart chambers were 
less profound for the exclusively hu-
man milk-fed group in comparison 
to those who were exclusively for-
mula fed, suggesting a potentially 
protective effect of human milk for 
heart structure. 
The researchers then identified 
potential reasons for why breast 
milk results in a lower risk of heart 
disease. Breast milk could help pre-
vent heart disease by better regulat-
ing hormones and growth factors, 
strengthening the infant’s immune 
system, reducing inflammation and 
by possibly improving the metabo-
lism of the child. 
Identifying the key components 
within breast milk that result in im-
proved heart health could pave the 
way for a more targeted approach 
to improve long-term cardiovascu-
lar wellbeing for those born prema-
turely. 
“It is becoming increasingly clear 
that premature birth results in long-
term adverse cardiovascular effects 
with important clinical consequenc-
es. There is a distinct lack of preven-
tative and therapeutic interventions 
available to alleviate those effects,” 
said Prof Afif EL-Khuffash, Honor-
ary Clinical Professor of Paediatrics 
at the RCSI and Consultant Neona-
tologist at The Rotunda Hospital. 
“The current evidence comes 
from observational studies and 
highlights the strong link between 
early breast milk administrations 
and improvement in long-term 
heart health, but it lacks concrete 
mechanistic explanations. More 
studies on the composition of breast 
milk could make clear exactly what 
causes these health benefits, which 
could in turn lead to better treat-
ment options.” 
The collaborative research group 
is continuing to study the effects 
of human milk exposure on heart 
function in very premature infants 
by using novel scans to measure 
heart function. They hope to dem-
onstrate that early human milk 
exposure in premature infants can 
lead to significant improvements 
in heart function over the first two 
years of age. The review article was 
published in the journal Paediatric 
Research and was written in col-
laboration with researchers from 
Harvard Medical School, the Uni-
versity of Oxford and University 
of Toronto. The full article is avail-
able at https://doi.org/10.1038/
s41390-019-0648-5.
Prenatal opioid exposure may alter brain function in babies
Connectivity in an area of the brain 
that regulates emotion may be al-
tered in infants exposed to opioids 
while in utero, according to a new 
study presented at the annual meet-
ing of the Radiological Society of 
North America (RSNA).
Opioid use in pregnancy has be-
come a major public health crisis. 
Opioids can have a devastating ef-
fect on maternal, foetal and infant 
health. When babies who have 
been exposed to opioids in utero are 
born, they suffer from drug with-
drawal, or a group of conditions 
known as neonatal abstinence syn-
drome (NAS). Exposure to opioids 
in utero is believed to have lasting 
consequences on brain develop-
ment and behaviour.
According to the researchers, NAS 
requires prolonged hospital stays, 
monitoring and, in severe cases, ad-
ditional treatment with opioids. Un-
derstanding how opioids affect the 
developing brain would be one of 
the important steps in early identifi-
cation and management of NAS and 
in improving neurodevelopmental 
and behavioural outcomes in these 
children.
“Little is known about brain 
changes and their relationship to 
long-term neurological outcomes in 
infants who are exposed to opioids in 
utero,” said Dr Rupa Radhakrishnan, 
Assistant Professor of Radiology and 
Imaging Sciences at Indiana Univer-
sity School of Medicine in Indianap-
olis, US. “Many studies have looked 
at the impact of long-term opioid use 
on the adult and adolescent brain, 
but it is not clear whether social and 
environmental factors may have in-
fluenced those outcomes.”
A team of obstetricians, neona-
tologists, psychologists and imag-
ing scientists collaborated to study 
the brains of 16 infants using resting 
state functional MRI (fMRI), which 
enables researchers to measure 
brain activity by detecting changes 
in blood flow. With resting-state 
fMRI, the connectivity between neu-
ral regions can be observed while the 
brain is at rest.
The research team investigated 
the functional connectivity of the 
amygdala, a region responsible for 
the perception and regulation of 
emotions such as anger, fear, sadness 
and aggression. The study group in-
cluded 16 full-term infants, includ-
ing eight exposed to opioids prena-
tally and eight who were not exposed 
to prenatal opioids, or opioid-naive. 
Imaging, including fMRI and ana-
tomical MRI, was performed while 
the infants were naturally asleep.
To determine the participation of 
the amygdala in the resting state net-
works, the team created brain maps 
and applied regions of interest for 
the left and right amygdala.
“Our early results show significant 
differences in the way the amygdala 
connects to different brain regions 
between the infants exposed to opi-
oids and the opioid-naive infants,” 
Dr Radhakrishnan said. “We still 
need to study what the clinical impli-
cation of this finding may be.”
He said larger and long-term out-
come studies are underway to bet-
ter understand the functional brain 
changes in prenatal opioid exposure 
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New cell models developed for ocular drug discovery
Researchers at the University 
of Eastern Finland have devel-
oped two new cell models that 
can open up new avenues for 
ocular drug discovery. The new 
cell models are continuously 
growing retinal pigment epi-
thelial cells, which have many 
benefits over the models cur-
rently used by researchers and 
pharmaceutical companies. 
The models were developed by 
Professor Arto Urtti’s Ocular 
Drug Delivery group at the Uni-
versity of Eastern Finland.
Pigment epithelial cells play 
a key role in, ie, age-related 
macular degeneration, which 
makes them an interesting tar-
get for drug therapy. The retinal 
pigment epithelium also regu-
lates the access of drugs from 
the blood stream into the eye 
and vice-versa, further high-
lighting the importance of this 
cell type for drug discovery.
Until now, cultivated retinal 
pigment epithelial cell lines 
have lacked both pigmentation 
and the blood-retinal barrier, 
which has complicated their 
use. 
The retinal pigment epithe-
lium (RPE) is characterised 
by strong pigmentation. Many 
drugs bind to cellular pigment 
and, consequently, can accu-
mulate in RPE cells. The new 
cell model makes it possible 
to study this accumulation in 
greater detail than before. 
In the new model, non-pig-
mented RPE cells can be re-pig-
mented by feeding them with 
melanin pigment.
Published in Scientific Re-
ports, the study also described 
the uptake of different drugs in 
melanosomes. According to the 
researchers, most drugs that 
bind to melanin at high levels 
were taken up by the melano-
somes, whereas the same was 
true only for a small number of 
drugs that bind to melanin at 
low levels.
“By using non-pigmented 
cells as controls, we were able 
to study how much of a drug 
given to the cells eventually 
ends up in the melanosomes. 
Next, we need to find out for 
how long the melanosomes can 
hold on to a drug, and wheth-
er this causes any harm. The 
accumulation of drugs in the 
melanosomes can, on the other 
hand, make it possible to target 
drugs at specific tissues,” post-
doctoral researcher Ms Mika 
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Medication safety ‘now a global goal’
Late last year, the RCSI played 
host to the Irish Medication 
Safety Network (IMSN) Annual 
Conference 2019, the 10th year 
in which the event has been 
held. The conference, which was 
held under the theme ‘Medica-
tion Without Harm: Responding 
to the Challenge’, was chaired 
by Ms Pat O’Brien, IMSN mem-
ber and Medication Safety Co-
Ordinator at Galway University 
Hospitals. 
Ms O’Brien introduced Ms 
Marita Kinsella, Director of the 
National Patient Safety Office at 
the Department of Health. Ms 
Kinsella referred to the “shared 
goal, which is indeed a global 
goal now, of ensuring the safety 
of medications” and in keeping 
with the range of healthcare pro-
fessionals attending the confer-
ence, she emphasised the need 





tory bodies and everybody else 
involved in the medication 
process is vital in promoting 
patient safety and responding 
to the global challenge that is 
medication without harm,” said 
Ms Kinsella. “The IMSN dem-
onstrates the importance of 
that collaboration by promoting 
the exchange of information on 
medication safety and facilitat-
ing national initiatives to help 
minimise risks to patients.
“Over the years, we have seen 
the benefits of IMSN collabora-
tions, with the publication of 
medication safety briefings and 
alerts, development of guidance 
on the management of identified 
high-alert drugs, and ‘sound-
alike’ and look-alike’ medi-
cines,” she told the conference. 
“The IMSN has led on a number 
of really important safety initia-
tives over the past year, but I par-
ticularly want to commend the 
IMSN on [the initiative] ‘Build-
ing a Medication Safety Pro-
gramme in a Hospital in Ireland 
— Fundamental Steps’… I want 
to recognise the IMSN’s lead-
ership in building a guidance 
document that provides hospi-
tals with the building blocks to 
design a safety programme and 
thereby give practical advice in 
addressing HIQA’s medication 
safety recommendations.
“It is this kind of collegial-
ity and collaboration that is es-
sential in our health service to 
embedding a culture of patient 
safety and quality.”
Ms Kinsella told the attendees 
that the Department of Health 
is contributing to EU-level ef-
forts to “consider initiatives” to 
minimise the risks to patients 
and also the impact on health-
care professionals of medicines 
[supply], the most serious issue 
facing the health service arising 
from Brexit,” she said. “Brexit 
will affect all of us, but in rela-
tion to medicines and medical 
devices, the Department is con-
fident that people will continue 
to have access to high-quality, 
safe and effective medicines and 
medical devices. In some limit-
ed circumstances, we may need 
to use therapeutic alternatives 
but if this is necessary, it will be 
informed by expert clinicians in 
their respective medical special-
ties and the expert role of phar-
macists and those of you with 
expertise in the safe use of medi-
cines will be critical in ensuring 
that we minimise the impact of 
Brexit for Irish patients.”    
Ms Kinsella also addressed 
the increasing importance of 
open disclosure and told the at-
tendees: “It’s very heartening to 
see that the IMSN is engaging in 
a very real way on open disclo-
sure and what it means with re-
gard to the safety of medicines,” 
she said. “As a health service, 
openness and honesty with pa-
tients must be at the heart of 
everything we do. Open disclo-
sure must happen in the right 
way and in all circumstances — 
patients have to be informed. 
“We have seen all too clearly 
arising from a number of seri-
ous patient safety incidents over 
recent years the impact that fail-
ure of open disclosure can have 
on patients. It’s important that 
we’re all committed to learning 
from these events and embed-
ding a culture of ensuring that 
patients are treated in a way 
that they would most like to be 
treated when things go wrong, 
that they perceive a sincere and 
genuine apology, and to be sure 
that what has happened to them 
will not happen to anybody 
else,” she continued.
“We need to ensure that the 
culture of trust and confidence 
between patients and clinicians 
prevails. Within the team at the 
National Patient Safety Office, 
we have been working on a new 
patient safety bill, which will fo-
cus on mandatory open disclo-
sure of the most serious patient 
safety incidents. This will ensure 
that patients and their families 
affected by a serious incident 
will be assured of receiving ap-
propriate and timely informa-
tion in relation to an unintended 
or anticipated serious event that 
may have occurred in relation to 
their care.”
Ms Kinsella added that the 
mandatory disclosure bill will 
also require notification of the 
most serious patient safety 
events and incidents to HIQA 
and the Mental Health Com-
mission, as appropriate, to 
ensure system-wide improve-Ms Marita Kinsella, Department of Health
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ments. However, she described 
the legislation as a “blunt tool” 
to embed a culture of openness 
and transparency in cases of 
serious incidents. 
“Ensuring that patients and 
their families are treated hon-
estly and openly when things 
go wrong also requires per-
sonal commitment from all of 
us who work in the health ser-
vice,” she said. 
Electric dreams in medications prescribing
The IMSN Annual Conference 
2019 heard from Mr Paul Tighe, 
IMSN Chair and Head of Phar-
macy at St Vincent’s University 
Hospital, Dublin. Mr Tighe pro-
vided an overview of the IMSN 
and its activities during 2019 
and told the attendees: “The 
IMSN is an entirely voluntary 
network and people are sur-
prised when they hear that,” he 
said. “Our full-time roles are in 
the hospitals in which we work 
— this is a collection of hospi-
tal pharmacy-based specialists 
from all the hospitals, not just 
the public ones, but also private 
ones. That’s very important, that 
we are very representative of all 
of the hospitals.”
The Network promotes medi-
cation safety through the ex-
change of information, as well as 
national and international initi-
atives and during 2019, the Net-
work published safety alerts on 
medication safety in pregnancy; 
tamoxifen and the potential for 
drug-drug interactions; medi-
cations for Parkinson’s disease; 
and a fresh review of intrave-
nous (IV) paracetamol. “We 
were particularly keen to review 
IV paracetamol and look at risks 
relating to dose-adjustment and 
risks around IV paracetamol use 
in children,” said Mr Tighe. 
For the start of this year, there 
is a working group focused on 
medication safety in operating 
theatres and another group fo-
cused on medication safety in 
the Electronic Health Record 
(EHR). “That’s very relevant 
when you take into account the 
number of hospitals that are 
moving towards using an EHR, 
particularly in the maternity 
sector,” he explained.
Mr Tighe presented national 
State Claims Agency data to 
show that of the clinical in-
cidents that were reported to 
NIMS during 2018, one-in-four 
were incidents that related to 
medication errors. Citing more 
data from the NIMS Clinical In-
sights report, Mr Tighe told the 
conference that regarding the 
areas in which medication er-
rors were occurring during the 
medications use process, one-
in-two such incidents happened 
at the prescribing stage. “That’s 
highly relevant, considering that 
prescribers traditionally report 
the least amount of incidents, 
but it’s also important when you 
consider where we are going 
with medication safety,” said Mr 
Tighe. 
“We have spoken at previous 
conferences about the hierar-
chy of intervention and about 
telling people to be more care-
ful, to introduce some policy in 
practice, but the more we can 
engineer things out of the sys-
tem, the safer they will be,” he 
said. “Every time we get a new 
recruit of medics, pharmacists 
or nurses in our hospital, we 
have to go through the same 
processes.”
Mr Tighe told the attendees 
that the most important devel-
opment in the past three years in 
Ireland in medication safety has 
been the strategic decision by 
HIQA to commence medication 
safety inspections and moni-
toring visits in public hospitals. 
“This has been a significant pro-
gramme that has really shone a 
light on all of the issues around 
not only medication safety, but 
also clinical pharmacy,” he said. 
“At the moment, I believe there 
have been approximately 60 
inspections, 54 of which are on 
the HIQA website. We have been 
given a gift from HIQA; 12 rec-
ommendations, seven of which 
are hospital-level and five that 
are national.
“We are quite good at some of 
these [recommendations] and 
we have made some progress 
on the national recommenda-
tions, particularly in sharing 
and learning from medication 
incidents, and also in trying to 
use electronic solutions where 
we can,” he continued. “But 
there are two that I would like 
to flag. The medication safety 
monitoring visits were as much 
about medication safety as they 
were about clinical pharmacy. 
Another recommendation that 
we have is to develop a national 
plan for comprehensive clini-
cal pharmacy services — it’s a 
huge task to do that, but it is also 
a huge opportunity in terms of 
the benefit that we will have if 
we can standardise some of the 
clinical pharmacy across all of 
our hospitals, regardless of the 
size of the hospital, and also the 
different types of scale that we 
deal with.”
Regarding one-in-two errors 
being at the prescribing stage 
of the medicine process, Mr 
Tighe spoke to the attendees 
Mr Paul Tighe, IMSN Chair
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about electronic prescribing. 
“We have seen significant pro-
gress with the NCIS [National 
Cancer Information System] 
and in maternity, and I think 
now is the time for all the hos-
pitals to make a huge effort to 
move towards EPMA [electron-
ic prescribing and medicines 
information] and to try to push 
the EPMA agenda as much as 
we can,” he stressed.
“There are only so many times 
we can train our prescribers 
and encourage people around 
medication safety but if we have 
EPMA, we can introduce deci-
sion support, we can introduce 
‘forcing functions’, and we can 
try to encourage safer prescrib-
ing.” In this regard, Mr Tighe 
offered St James’s Hospital in 
Dublin as an example that other 
hospitals could follow.
Unpublished data shows significant improvements in hospital 
medication safety
The IMSN Annual Conference 
2019 also saw a joint presen-
tation titled ‘Collaborative 
Approach to Reducing Hos-
pital-Acquired Venous Throm-
boembolism from a Patient, 
Clinician and Group Hospital 
Manager Perspective’. The at-
tendees were given differ-
ent perspectives on this topic 
from Ms Annemarie O’Neill of 
Thrombosis Ireland, Prof Fion-
nuala Ni Ainle, Consultant Hae-
matologist at the Mater Miseri-
cordiae University Hospital and 
Rotunda Hospital in Dublin, 
and Prof Mary Day, CEO of the 
Ireland East Hospital Group. 
This was followed by a pres-
entation by Ms Aoife Lenihan, 
Regional Manager of Health-
care Regulation with HIQA, 
who spoke on the theme ‘HIQA 
Phase II Medication Safety Mon-
itoring in Hospitals’. Ms Lenihan 
provided an overview of this 
phase of the programme, which 
has been running for four years, 
and said the public must be fully 
assured that national standards 
in medication safety are being 
met. For pharmacists who seek 
details of the programme, Ms 
Lenihan urged them to consult 
a guidance document published 
by HIQA on its website.
Ms Lenihan presented some 
previously-unpublished infor-
mation on some findings from 
the past two years and told the 
seminar: “In that time, we have 
conducted 20 inspections in 19 
hospitals, visiting one hospital 
twice in that time-frame,” she 
explained. “Comparing what we 
found in 2016 and 2017 in rela-
tion to governance, in the first 
two years of the programme, we 
estimated that approximately 
60 per cent of the hospitals that 
we inspected had a functioning 
drug and therapeutics commit-
tee. When we went back out in 
2018 and 2019, this had signifi-
cantly improved, in that all 19 
hospitals had these functioning 
committees.
“In the first two years, we 
found very few hospitals had a 
formal medication safety strat-
egy to be very clear on what the 
short-, medium- and long-term 
goals were for a particular hospi-
tal,” said Ms Lenihan. “This had 
improved to 10 hospitals having 
a very structured and clear strat-
egy in the past two years and it’s 
fair to say the hospitals that had 
not formally developed a strate-
gy had ways whereby they could 
identify their priorities, articu-
late them, and they had action 
plans to track improvement to 
ensure they were working in a 
systematic way to achieve those 
goals.”
Quality of risk management 
system was shown to be “very 
solid” across all hospitals over 
the past two years, Ms Lenihan 
said, including risk registers 
to escalate high-risk issues in 
medication safety and analysis 
of incident reports, however she 
revealed that proactive risk as-
sessments were quite rare. 
“These were more common 
in the ‘leading’ hospitals, where 
instead of focusing on just in-
cident reporting, there was a 
focus on what could potentially 
go wrong and taking proactive 
measures. This is an area that 
could potentially be improved.”
Most of the hospitals showed 
increases in incident reporting, 
but the culture of reporting can 
always be improved, said Ms 
Lenihan, who pointed out that 
pharmacists and nurses most 
often reported safety incidents. 
On the day of inspection, sam-
ples would be looked at from 
eight high-risk medications 
identified by HIQA, including 
anticoagulants. “These are the 
highest-risk medications that 
perennially come up in inci-
dents and the only medications 
that we identified in very seri-
ous events,” she explained. In 
this regard, policies and pro-
tocols were designed to guide 
staff and avoid inadvertent 
double-dosing.
It was also decided that for 
the first time, the inspection 
team would visit operating 
theatres, said Ms Lenihan, and 
areas that provide procedural 
sedation outside of the theatre. 
“In-theatre is a unique situa-
tion, where there are multiple 
high-risk medications, high pa-
tient throughput and complex 
procedures, which makes it a 
very high-risk area,” she said. 
“In general, the drawing-up and 
 Ms Aoife Lenihan, HIQA
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labelling of syringes was in line 
with best practice… hospitals 
were using internationally-rec-
ognised labelling systems and 
in general, practitioners were 
drawing-up drugs and using 
them themselves, rather than 
leaving them for another practi-
tioner, and they were maintain-
ing custody of those drugs and 
disposing of them at the end of 
a procedure.”
However, while a limited 
number of sites were inspected 
for procedural sedation, the in-
spection team found variations 
in governance and oversight, 
with only two hospitals having 
a specific procedural sedation 
safety committee. Procedural 
sedation in endoscopy is gener-
ally “very well done,” Ms Leni-
han added. Overall, the inspec-
tions also revealed increases in 
medications reconciliation and 
“where there is a clinical phar-
macy service, medication safety 
is greatly improved,” she said. 
Five of the 19 hospitals inspect-
ed had a very limited or purely 
dispensing pharmacy service 
and hospitals that did not have a 
formulary are working on devel-
oping local formularies, while 
most hospitals had access to in-
formation for staff at the point of 
care, she said.
However, some hospitals’ 
medication safety monitoring 
was limited to using nursing 
metrics and Ms Lenihan told 
the conference in conclusion: 
“I’m sad to say that the medica-
tion safety monitoring in its cur-
rent guise will conclude in 2020, 
when we will have done more 
than three years of work,” she 
said. “But on a positive note, it’s 
not something that we will leave 
behind. We plan to work on and 
develop our approach to moni-
toring and this is something we 
will maintain; whatever way our 
monitoring approach chang-
es… there will need to be a lot 
of communication with stake-
holders, including yourselves, 
and stakeholder engagement in 
changing the way we monitor 
hospitals.”
At the heart of anticoagulation
The IMSN Annual Conference 
2019 also heard from Mr Sotiris 
Antoniou, Consultant Pharma-
cist in Cardiovascular Medicine 
and Chair of the International 
Pharmacists Anticoagulation 
Taskforce (iPACT), UK. Mr An-
toniou provided an overview of 
collaborative care in anticoagu-
lation and provided a number 
of case studies to illustrate how 
collaborative work can help to 
improve patient outcomes.
“With the NOACs, there is 
some good data to show that 
even after one year of treatment, 
the discontinuation rate is be-
tween 33 and 50 per cent,” said 
Mr Antoniou. “In fact, if you look 
at the trials on NOACs in stroke 
prevention and atrial fibrilla-
tion (AF)… the discontinuation 
rate due to adverse events is ap-
proximately 20-to-25 per cent in 
a randomised, clinical trial. So 
we are not surprised that these 
figures are replicated in the gen-
eral population.”
Regarding in medicines that 
cause hospitalisations due to 
an adverse event, he told the 
attendees that anticoagulants 
“will always be seen in the top-
three, if not the number-one… 
warfarin is the number-one 
drug associated with hospitali-
sations in US hospitals. As you 
might expect, the majority of 
the reasons for this related to 
bleeding and the number-one 
concern was around intracra-
nial haemorrhage.” The average 
INR for a person taking warfarin 
and admitted to hospital with 
an intracranial haemorrhage is 
typically 2-to-3, he said.
Along with the ageing popula-
tion, rates of AF are increasing 
and Mr Antoniou referred to 
international guidelines, which 
state that opportunistic screen-
ing for AF in patients aged over 
65 years, involving pulse-taking 
followed by an ECG, is recom-
mended to allow timely detec-
tion of the condition. In 2016, iP-
ACT organised for hospitals and 
community pharmacies in five 
countries to run pulse aware-
ness initiatives, he added.
One challenge for hospital 
pharmacists is that patients 
are rarely on the same medi-
cines they end up taking on 
discharge, said Mr Antoniou, 
who spoke about the iPACT in-
terprofessional guidelines on 
anticoagulation. 
“Among the top recommen-
dations are the importance of 
communication in the transfer-
of-care between healthcare 
settings; ongoing medications 
adherence; medicines reconcili-
ation; and medications review. 
We know that transfer of care 
is a particularly high-risk area 
because of lack of communica-
tion or inconsistent communi-
cation.”
Healthcare staff often the ‘second victims’ in adverse incidents
The IMSN Annual Conference 
2019 heard presentations from 
Mr Dan Burns, Pharmacy Di-
rector at Pharmapod, on the 
theme ‘Advancing the Global 
Patient Safety Agenda’ and Ms 
Ciara Kirke, Clinical Lead at the 
National Medication Safety Pro-
gramme at the HSE, who deliv-
ered an overview of ‘The Know 
Check Ask Campaign — Mobi-
lising People Power for Medica-
Mr Sotiris Antoniou, iPACT 
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tion Safety’. 
Attendees also heard a pres-
entation from Ms Ann Duffy, 
Senior Clinical Risk Advisor at 
the State Claims Agency (SCA), 
who spoke on the topic ‘Medica-
tion Safety and Open Disclosure 
— An Evolving Landscape’. Ms 
Duffy told the conference that 
staff often do not get the sup-
ports they need following an 
adverse event, leading to them 
sometimes being described as 
“the second victim”. She told the 
attendees: “Medicine is dynam-
ic, it is evolving, it’s complex. 
We are always going to have in-
cidents and we are always going 
to have claims. What we need to 
focus on is how we react to those 
incidents and claims and how 
we manage our staff following 
those events.”
A lot of the SCA’s work re-
volves around data and the Na-
tional Incident Management 
System (NIMS) to identify trends 
and mitigate potential risks, as 
well as the nature of claims and 
how they came about and a re-
curring theme is poor commu-
nication or lack of communica-
tions. In pharmacy, incorrect 
prescriptions and errors around 
drug dosage are also recurring 
themes, said Ms Duffy.
She described the “domino ef-
fect” adverse events can have on 
staff and she outlined the top-10 
injuries in acute services, such 
as cuts, lacerations and postpar-
tum haemorrhages. In terms of 
medication incidents, she told 
the attendees: “There were only 
10,000 reported in 2018 and it 
will be similar for 2019, so we 
are well aware that the ‘iceberg’ 
is there and we are only seeing 
the very tip of it.”
On the topic of who reports 
incidents most, Ms Duffy said: 
“Clinical pharmacists are pick-
ing up a lot of these medica-
tion incidents at ward level, fol-
lowed by nursing and midwives 
and doctors… ” She outlined 48 
claims made between 2011 and 
2016 and estimated the costs of 
these to be around €3 million, 
however the legal and expert 
costs often equal or exceed the 
amount a plaintiff will receive. 
Ms Duffy presented a case 
study to illustrate a claim of 
negligence, pointing out that 
for negligence to be proven, it 
must be established whether a 
duty of care existed in the first 
place. She also outlined a defi-
nition of actions to be taken on 
adverse incidents from Austral-
ian authorities, which includes 
“expressing regret for what 
happened, keeping the patient 
informed, providing feedback 
and taking steps to prevent re-
currence. 
“Open disclosure is about 
good, effective communication 
with patients and their fami-
lies.” Patients should be told 
quickly about medication er-
rors rather than waiting for a 
process to begin, which could 
take days or weeks, she said.  
“Medicine is complex and 
incidents will continue to hap-
pen,” Ms Duffy concluded. 
“When things go wrong, we have 
to know how to look after our 
staff and help them. I say this 
to a lot of students — no-one is 
immune to being involved in an 
incident. Practical and timely 
support are important — there 
is the ASSIST model, which I 
myself used recently, and con-
fidential settings are important 
for staff to discuss an incident 
and how it affected them… de-
briefing is also important and 
occupational health has a role 
in this area, as do employee as-
sistance programmes.”  
Pharmacists front-and-centre in medication safety
Regional Manager of Health-
care Regulation at HIQA Ms Ao-
ife Lenihan has said that phar-
macists are leading the way in 
striving for medication safety 
in Irish hospitals. Ms Lenihan 
was speaking with Irish Phar-
macist (IP) following her pres-
entation at the IMSN Annual 
Conference 2019, which was ti-
tled ‘HIQA Phase II Medication 
Safety Monitoring in Hospitals’.
Ms Lenihan commented: 
“From what we see on inspec-
tion, pharmacists [as part of the 
multidisciplinary team] are lead-
ing the way and are very often the 
drivers for medication safety. We 
also made the point in our over-
view report in 2018 that there are 
gaps in clinical pharmacy servic-
es and we have included this as a 
national recommendation.”
Ms Lenihan also touched on 
the general public awareness 
of the importance of hospital 
pharmacists in patient care in 
comparison to the high level of 
awareness that exists around the 
value of community pharmacists. 
“There is definitely potential to 
raise awareness in this regard,” 
she said. “Anything in the public 
domain that raises awareness of 
the role, and promotes the role 
of clinical pharmacists within a 
hospital setting, and to educate 
them about the evolving role of 
pharmacists over the years within 
hospital care is good, as well as 
highlighting their important role 
in ensuring medication safety.”
Ms Lenihan was also asked 
about the fact that medication 
safety monitoring in its current 
guise will conclude in 2020, and 
what her hopes and aspirations 
may be when that happens in 
terms of the continued drive for 
medication safety. “Back in 2016, 
this was identified as a key area for 
HIQA to focus its monitoring pro-
grammes on,” she told IP, “so fu-
ture monitoring of healthcare by 
the healthcare team will include 
aspects of medication safety.” 
Ms Ann Duffy, State Claims Agency
FEATURE  |  Fee cuts 
16 VOL 22 ISS 1    JANUARY 2020
In December 2019, the Irish Pharmacy Union (IPU) welcomed the “sensible decision” by Minister for Health Simon Harris not to proceed with proposed 
“savage cuts in fees” to pharmacies and, in-
stead, to recommit to early talks on a new 
pharmacy contract and investment in phar-
macy services.   
When the proposed cuts were announced 
in October, Ireland’s 2,300 community 
pharmacists were left “deeply shocked and 
concerned”, according to the IPU. 
Any funding cuts would “go completely 
against” the Government’s Sláintecare strat-
egy, which aims to keep health services in 
the local community, it added.
With this controversy now seemingly put 
to bed, pharmacists can return their atten-
tion to the development of a new contract 
that will facilitate an expansion of healthcare 
services within pharmacies. 
 “The contract we have for pharmacies 
has been in place since 1996,” IPU Secretary 
General Mr Darragh O’Loughlin explained. 
in late November. “The Internet didn’t even 
exist when this contract was signed. It was 
a modern contract back then, but it is com-
pletely outdated now and not fit-for-purpose 
anymore and pharmacists and the public 
need a new pharmacy contract that reflects 
how pharmacy should be practised in the 
21st Century.”
MINOR AILMENTS
What should 21st Century pharmacy look 
like? A document published in 2016 by the 
Pharmaceutical Society of Ireland (PSI), 
provided a comprehensive overview of 
the healthcare services that may become 
available in pharmacies in the future (see 
panel overleaf). One such service is a minor 
ailments scheme. 
A feasibility trial into a minor ailments 
service in Irish pharmacies was conducted 
in 2016. It was piloted across 19 pharmacies 
in four towns (Kells, Roscommon, Macroom 
and Edenderry) for three months.
The medical conditions included in the 
trial were dry eye, dry skin, scabies, thread-
worms and vaginal thrush. In a response to a 
parliamentary question in November 2018, 
Minister Harris said the study successfully 
tested operational and administrative proce-
dures, but the patient take-up was small (121 
consultations) and no meaningful clinical or 
outcome data emerged. 
More extensive trialling would be required 
if this was to be progressed, he said. 
The Irish Medical Organisation (IMO) has 
expressed concern over a minor ailments 
scheme in pharmacies and about some other 
potential extensions to pharmacists’ scope of 
practice. It has also frequently pointed to the 
importance of a clear distinction between 
the prescriber and dispenser of medicines.
Dr Denis McCauley, Chair of the IMO GP 
committee, said there is a substantial train-
ing requirement in order to become skilled 
in differentiating minor from non-minor 
ailments. 
“You would almost have to do a casualty 
job for six months to be able to identify a 
minor ailment as opposed to a non-minor 
ailment. You can’t just become a minor 
ailment ‘superstar’ overnight; it would take 
quite a lot of training to actually do it. Now, 
that is not being facetious or arrogant. Invari-
ably, you will find they will still be referred to 
the doctor,” he stated. 
But according to Mr O’Loughlin of the IPU, 
such schemes have been operating well in 
other countries.
“And the pharmacists all have protocols 
they follow in order to ensure they have cor-
rectly identified what the ailment is, and that 
they are providing the correct treatment. This 
is happening in Scotland and it’s happening 
in Wales,” stated the IPU Secretary General.   
“In Scotland, it was originally only for 
certain citizens, the ones who had eligibility 
for free prescriptions and the elderly, and 
now they are expanding it out to the whole 
population because it has been a success. 
They have found that symptom resolution 
rates, in other words appropriate and suc-
cessful treatment rates, for minor ailments in 
pharmacies can be up in the 90s in terms of 
percentage.
“The British Journal of General Practice 
found the pharmacies were treating them as 
successfully as GPs but that it was done at 
a lower cost to the health system. So while 
I respect the view of the IMO, and we don’t 
claim to be doctors — no pharmacist out 
there is pretending to be a doctor — I am a 
pharmacist, I want to be a pharmacist, but I 
want to practise pharmacy to the top of the 
scope of pharmacy practice.”
A minor ailments scheme is essentially 
operating for private patients, according to 
Mr O’Loughlin. He said people without a 
medical card often call into a community 
pharmacist with symptoms and receive an 
over-the-counter (OTC) medicine as treat-
ment. 
“They don’t go to a doctor. So if a private 
patient has indigestion, or a headache, or 
Where to now
for pharmacy?
Threatened fee cuts to community pharmacists will not now proceed, but it remains unclear when 
and how their role will be expanded in the future. Catherine Reilly interviews representatives from 
the pharmacy and medical professions and finds there are differences of opinion
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constipation, nausea, hay fever, skin aller-
gies, anything like that — they will invariably 
go to a pharmacy first. If it looks like it re-
quires a doctor, the pharmacist will say ‘you 
actually need to see your GP about that’.”
In contrast, public patients often present 
to their GP with a minor ailment as they 
need a prescription to avail of the OTC medi-
cation free of charge. 
“We are just saying that public patients or 
medical card-holders should have the same 
access level to treatment as private patients 
have. In one year in Ireland, we have almost 
a million medical card prescriptions written, 
where there is just medicine on it and the 
medicine could have been bought without a 
prescription. 
“So that suggests those are minor ailments 
which, if you were a private patient, you 
probably would have just gone to the phar-
macy and got your treatment there and then. 
I can see what the IMO is saying but I don’t 
agree with their suggestion that there is some 
risk inherent in pharmacists providing treat-
ments to medical card-holders who have 
minor ailments because those risks have not 
manifested in pharmacists prescribing non-
prescription medicines to private patients.”
‘FRAGMENTATION OF CARE’
Dr McCauley told this publication objec-
tions within his profession were not about “a 
‘greedy GP’ keeping everything to himself”, 
as some might perceive it. 
He said GPs were concerned about “frag-
mentation of care, cherry-picking; various 
things like that”. 
Dr McCauley gave the example of phar-
macists potentially being allowed to provide 
the oral contraceptive pill without a doctor’s 
prescription. He said pharmacists would not 
be in a position to give a full range of con-
traceptive options, principally long-acting 
reversible contraceptives (LARCs), which are 
recommended for many women in terms of 
health and effectiveness.    
 “So giving a pharmacist one function, or 
one ability to do one thing — guess what 
happens; that pharmacist will only do that 
thing. Whereas if a GP has five options, they 
will choose what is best for the patients.”
Again, Mr O’Loughlin viewed matters 
differently. 
“The pharmacist is perfectly capable of 
talking through all the options with a woman 
looking for contraception, telling her about 
LARCs in addition to the pill and other meth-
ods, and explaining the benefits,” he said.
“And then a woman will decide, ‘I want to 
get the LARC as that sounds like it will suit 
me’, and we will refer them to a GP who does 
it because not all GPs, for example, fit the 
coil or fit Mirenas. So you’d refer them to a 
doctor who does that. 
“We already know how to refer people to 
a doctor to provide a service to them. But 
last year in Ireland, there were two million 
packs of [contraceptive] pills dispensed in 
pharmacies on prescription; those prescrip-
tions were written by doctors. So doctors are 
prescribing that level of oral contraceptive 
pill out there, to women who choose to use 
that method of contraception. 
“What we are talking about is giving wom-
en the choice, so they wouldn’t be obliged to 
go to a pharmacy; they could still go to a doc-
tor. We are not going to oblige them to take 
the pill; they can still choose to have a LARC. 
But women who choose to go to a pharmacy 
to get the pill should be able to get it. 
“They are already doing this in New Zea-
land, many states across the US, and parts 
of Canada. They have actually done a study 
in Oregon state, which was the first US state 
to introduce pharmacists’ prescribing of 
the pill, and they were able to quantify the 
number of unwanted pregnancies that had 
been avoided and the consequent financial 
saving to the health system and the social 
care system as a result of those pregnancies 
not happening.”
E-HEALTH
On a broader note, Ireland’s poor e-health 
infrastructure remains a barrier to extend-
ing pharmacists’ practice, according to Mr 
O’Loughlin. 
“In Ireland, we don’t have a proper e-
health infrastructure, we don’t have [system-
wide] online health records, GPs can’t see 
records in a hospital, the hospital can’t 
see GP records, nobody can see pharmacy 
The existing role that community pharmacists 
play in “supporting patients treating minor and 
self-limiting conditions” should be further ex-
panded, according to a document published by 
the regulator of pharmacists and pharmacies. 
Future Pharmacy Practice in Ireland, pub-
lished by the PSI in 2016, noted that an increase 
in the reclassification of medicines from pre-
scription to non-prescription status had oc-
curred in recent years. 
“There has been successful implementation 
of the reclassification of some medicines, such 
as the emergency hormonal contraception 
(EHC), which is now available for patients di-
rectly from the pharmacist. 
“In addition, recent legislation has enabled 
appropriately-trained pharmacists to supply 
and administer certain prescription-only medi-
cines to patients in the event of an emergency, 
including epinephrine (adrenaline), salbuta-
mol, glyceryl trinitrate, glucagon, and naloxone. 
“Both of these initiatives demonstrate the role 
that pharmacists can play in directly treating pa-
tients in the community. These initiatives, com-
bined with the availability of a private patient 
consultation area within community pharmacy, 
creates the potential for further development of 
this role. Other jurisdictions have introduced 
structured schemes for pharmacists to provide 
advice and treatment if required to patients for 
specified minor illnesses and complaints, ie, mi-
nor ailments scheme.”
According to the report, “our research has 
confirmed that in other jurisdictions, while re-
ferral to the GP or acute setting is extremely im-
portant, it can also work in the opposite way and 
reduce pressure on the health system”. 
The report cited data from one large emergen-
cy department (ED) and two general practices in 
Scotland, which showed that at least 5 per cent 
of ED and 13 per cent of GP attendances were for 
common ailments “that could have been man-
aged in a community pharmacy”.
The document also stated that mechanisms 
should be explored to enable pharmacists and 
GPs to work more closely together to support 
patients in chronic disease management. “This 
could include supplementary prescribing activi-
ties, such as dosage adjustment or therapy con-
tinuation by the pharmacist in line with agreed 
protocols,” according to the document.
The steering group for the report included De-
partment of Health and HSE officials, a patient 
representative, pharmacists and pharmacy rep-
resentatives, and a Medical Council representa-
tive (GP Dr Ruairi Hanley).
“The report is the result of a research project 
that included an extensive consultation pro-
cess involving patients, pharmacists and other 
healthcare professionals, other regulatory bod-
ies, and engagement with policy-makers,” a PSI 
spokesperson said. 
The PSI has met with stakeholders and organ-
isations “to share the findings and recommen-
dations and inform policy development and 
healthcare reform”.
PSI REPORT PROVIDED VISION FOR FUTURE PHARMACY PRACTICE 
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records, and so on…
“So look at Canada; patients are diagnosed 
by their physician there with high blood 
pressure — hypertension — the physician 
does out the care plan, ‘these are the medi-
cations you are going to use, the pharmacist 
is going to monitor your blood pressure, the 
pharmacist is going to adjust the dose of 
these medicines up or down as appropriate, 
and put that information onto your electron-
ic health record and I will see it here’.
“‘And if your blood pressure is not con-
trolled, you are going to be referred back 
here [to the doctor] and we’re going to take 
control of it’. But for the majority of the popu-
lation for whom the medication the doctor 
prescribes actually works, the pharmacist is 
doing the monitoring, and can even extend 
the prescription out if it is working and refer 
people back to the doctor where the medi-
cine isn’t working. 
“Whereas today in Ireland… private 
patients get a six-month prescription, they 
go away and take the medicine and nobody 
is checking whether it is working or not, and 
nobody is checking that they are getting the 
right dose, and if they have achieved their 
target blood pressure. And there is inter-
national evidence that shows that blood 
pressure control in Ireland, particularly for 
male patients, is one of the poorest in the 
countries they looked at, whereas Canada is 
one of the best. That saves lives in Canada.”
There would be additional training 
requirements for pharmacists if their role 
developed, as had occurred when the 
national influenza vaccination programme 
commenced in pharmacies. “There are some 
services where if they were to be rolled-out 
in pharmacy, they would require additional 
training, there is no doubt about that,” said 
Mr O’Loughlin.
Both Dr McCauley and Mr O’Loughlin 
emphasise that the relationship between GPs 
and pharmacists on-the-ground is positive. 
But clearly, the two unions strongly disagree 
on how the relationship will develop.
Dr McCauley welcomed the inclusion 
in the recent agreement between the IMO 
and Department of a pharmacist-supported 
medicines usage review process in primary 
care. It will aim to support GPs in safe pre-
scribing and reduce high-risk prescribing, 
arising due to the age of the patient, and 
potential comorbidities and co-prescription. 
This will be introduced and targeted at medi-
cal card/GP visit card patients aged over 75 
years resident in the community.
The pharmacists, employed by the HSE 
and based regionally, will be able to visit 
GP practices and make suggestions on safer 
prescription.
It is these traditional areas of practice 
where the IMO believes the profession 
should focus their efforts. 
Mr O’Loughlin considers it possible there 
is “a fear in one profession that if a new 
service is provided by a different profession, 
and funding goes into it, that they will some-
how be at a loss”.
“GPs should be paid for what they do and 
should be paid properly,” Mr O’Loughlin 
emphasised, “but they should be given the 
level of support that allows them to spend 
meaningful amounts of time with patients 
who need meaningful amounts of time and 
not be rushed, having to get through a wait-
ing room of people who could have been 
dealt with in a pharmacy.”
ICGP
Meanwhile, the ICGP issued a statement 
to this publication conveying a much more 
open position on expanding the pharma-
cists’ role, when compared with the IMO. 
The College will have a particular insight into 
developments in pharmacy through CEO 
Mr Fintan Foy, who is currently serving his 
second term on the Council of the PSI. 
In regard to a minor ailments scheme, an 
ICGP spokesperson said community phar-
macists already treat several minor ailments 
“such as minor coughs and respiratory 
infections and some skin infections, among 
other ailments, and this of course helps to 
reduce pressure on the hospital emergency 
services and on other parts of the health 
service. 
“A community pharmacist-provided minor 
ailments scheme would require clear guide-
lines, protocols and governance structures, 
as well as training of pharmacy support 
staff.”
As to the potential future introduction 
of independent pharmacist prescribers, 
as well as pharmacist supplementary pre-
scribing as part of shared care with a GP, 
the spokesperson said: “Pharmacists and 
GPs already enjoy a close working relation-
ship and a good level of trust and mutual 
respect has been established through years 
of working together. A highly-trained phar-
macist prescriber under the governance 
and supervision of the managing GP would 
be an additional valuable resource in the 
community. 
“If care is shared with GPs and is guided 
and directed by the GP, then a pharmacist 
prescriber would add to the community 
support team for patients. Pharmacist pre-
scribers would require extra training and 
thorough and comprehensive guidelines and 
protocols in order to ensure patient safety 
and wellbeing.”
On whether the College could have any fu-
ture role in the training of community phar-
macists, the spokesperson said pharmacists 
and GPs have their own separate education 
and professional competence schemes. 
“However, the ICGP would be very happy 
to meet with the PSI and the Irish Institute 
of Pharmacy to discuss areas of mutual in-
terest in the areas of education and service 
provision.”
The Department of Health is clear that it 
sees the role of pharmacists in Irish health-
care as evolving. But it is providing limited 
detail on what this new model may look like.
 “The Minister will be seeking to put 
in place a contractual agreement that is 
fit-for-purpose in a healthcare system that 
is increasingly seeking to tilt the balance 
of care towards a strengthened primary 
care system,” according to a Department 
spokesperson. 
“The intention would be that the vision 
and approach which underpins Sláintecare 
would be mapped-out for community phar-
macy; a primary care model, integrated with 
other health policies as part of a multidis-
ciplinary approach to healthcare. The way 
forward will require the expansion of both 
the scope of practice and the range of public 
services provided in community pharmacy.
“An overriding principle in that proposed 
engagement with pharmacy representatives 
has to be value for money, ensuring that 
any new service delivery actually improves 
health outcomes and benefits for patients. 
All proposals, including treatments for minor 
ailments, will be for discussion under the 
proposed contract reform.” ●
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At the National Pharmacy Conference last May, it was with guarded optimism that I listened to the Minister for Health paint a picture of a rosy immediate future for Irish pharmacists, with gushing enthusiasm for the role pharmacists play in 
healthcare and a commitment, if somewhat vague, to new contract talks. With a forest 
of hands ready to shoot up towards the ceiling, the Minister had a clearly ‘pressing 
commitment’ and wasn’t around for the Q&A after his address. The optimist in me 
imagined that he was rushing back to his office to work on drafting a new contract.
Fast-forward to October, when the bombshell dropped that new, savage cuts were to 
be imposed on pharmacy fees. There was a collective 'thud' as around 2,300 jaws hit the 
floor in community pharmacies nationwide — 2,301, if you include the offices of Irish 
Pharmacist. I took no pleasure in having my cynicism confirmed.
Taking another time-jump to December — having already penned the most scathing 
editorial I’ve ever written — and it was abruptly announced that the proposed fee cuts 
were not going ahead and the Minister had re-committed to new contract talks. The 
proposed cuts were confusing, but no less so than the Minister’s reversal. The editorial 
found its new home in the recycle bin.
As the old saying goes, that kind of raised more questions than it answered. Who 
proposed these cuts in the first place before they were announced? Was it a decision 
by the Minister himself, or was he influenced by some clueless advisors who foolishly 
thought hammering pharmacists further would be a good idea? What happened in 
between the announcement that cuts would be imposed and the press release stating 
that they would not in fact go ahead? And even if he was badly advised on imposing 
further cuts, what the hell was Minister Harris thinking in going along with it? Was he not 
concerned about being perceived as something of a hypocrite, given the contents of his 
address at the National Pharmacy Conference? 
But most intriguing of all, what happened at the meeting between the IPU 
representatives and Minister Harris on 5 December? Was he cajoled, 
persuaded, or did Mssrs Connolly and O’Loughlin bring along Luca 
Brasi to make the Minister an ‘offer he couldn’t 
refuse’? Whatever they did, it clearly 
worked and the Minister must have 
required treatment for whiplash injury.
Perhaps a Sir Humphrey-type figure had 
a quiet word in the Minister's ear to remind him 
that pharmacists vote too. With a general election on 
the horizon, the cynic in me is tugging at my sleeve, 
warning of another potential volte face when that small 
matter is put to bed.
Not withstanding all of the above, I sincerely wish all 
of our readers a smooth ride in 2020 along the road to a 
hopefully bright future for the profession. ●
THAR AN GCUNTAR AS GAEILGE
Prionsabal a hAon: Cuir an t-othar chun tosaigh i gcónaí. Is é an 
prionsabal seo an ceann is tábhachtaí i mo thuairimse, ós rud é go 
bhfuil sé mar bhunchloch an Chóid Iompair. Coinnigh an t- othar 
i gcroílár an chúraim a sholáthraíonn tú; Bíodh a bpríomhfhócas 
ar a sláinte, a bhfolláine agus a sábháilteacht i gcónaí; Agus é 
sin á dhéanamh agat, tá tú ag cinntiú go n-aithnítear riachtanais 
an othair agus go bhfreagraíonn tú ar bhealach díniteach agus 
gairmiúil. Coinníonn sé seo luachanna an othair chun tosaigh san 
idirghníomhaíocht. Feabhsaíonn sé seo eispéireas an othair. Tríd do 
scileanna agus eolas gairmiúil a chur i bhfeidhm, cinntíonn tú arís 
go bhfaigheann an t- othar cúram sábháilte agus éifeachtach. Mar 
fhocal scoir, ag aithint go mbíonn tionchar díreach ag do chinntí 
agus do ghníomhartha mar Chógaiseoir ar an gcúram a bhíonn ann, 
fiú i gcúinsí nach raibh tú ag obair go díreach leis an othar. Cén chaoi 
a gcinntíonn Cógaiseoir go bhfuil siad ag cur an chéad Phrionsabal 
Cleachtais i bhfeidhm sa Chód Iompair nua-athbhreithnithe? 
1. Mar a luadh thuas, tá cur i bhfeidhm eolais, cur i bhfeidhm 
scileanna agus úsáid chinnteoireachta bunaithe ar fhianaise mar 
chuid lárnach de Phrionsabal a hAon agus, rud is tábhachtaí, 
cinntíonn sé go bhfuil an t-othar ag fáil an chaighdeáin is airde 
cúraim is féidir. 
2. Tréith; ardchaighdeán, tá go leor cógais ag cógaiseoirí, ag 
feidhmiú a gcumas chun cóir leighis a chur ar gach othar ar 
bhealach measúil, díniteach agus cúirtéiseach. 
3. Ní mór úsáid a bhaint as d’aitheantas ár luachanna, creidimh, 
éagsúlacht agus féiniúlacht chultúrtha na n-othar a dtéann tú i 
dteagmháil leo. Tá poitéinseal éagsúil cultúrtha in Éirinn, agus de 
réir, tá tionchar ag roinnt creidimh ar shláinte agus ar an dóigh a 
mbítear ag súil le sláinte nó ag teacht léi. 
4. Prionsabal an toil nó an cead a urramú. Cinnte go bhfuil tú ag cloí 
leis na rialacháin reachtúla go léir. 
5. Bheith ábalta cinntí othar a aithint agus a urramú, go háirithe i 
gcásanna inár féidir leo cóireáil nó seirbhísí a dhiúltú. 
6. Cosc a chur ar aon cheann de do thuairimí pearsanta ó chúram an 
othair a chur i mbaol. 
7. Déileálfaidh Cógaiseoir a chloíonn leis an gCód nua-
athbhreithnithe le gach duine go cothrom lena n-áirítear daoine 
leochaileach, daoine faoi mhíchumas intleachta agus aon 
mhíchumas eile, a n-aithnítear go minic mar Chógaiseoirí in Éirinn. 
8. Bheith muiníneach maidir le hábhair imní a ardú leis na húdaráis 
ábhartha más rud é go bhfuil baol tionchar a bheith acu ar shláinte 
an othair, nó a d’fhéadfadh tionchar diúltach a imirt ar chúram othar 
mura dtugtar aghaidh orthu. 
Mar nóta scaradh, is é an t-othar a choinneáil chun tosaigh an rud is 
tábhachtaí i gcónaí. Mar sin féin, tá luach agat féin mar dhuine agus 
mar dhuine oiliúint ghairmiúil. Ná déan dearmad ar an méid sin. 
Send your comments to pat@greenx.ie or by post to  
The Editor, Irish Pharmacist, GreenCross Publishing Ltd, 
Top Floor, 111 Rathmines Road Lower, Dublin 6, D06K5F6.
MARK JORDAN is a 
community pharmacist 
based in Castlebar, Co Mayo. 
He is an elected member 
of the PSI Council, author 
of The Weekly Nugget on 
PharmaBuddy and host to 
the PharmaBuddy Podcast.
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T
here’s a great line in the 1990s 
movie, Dangerous Liaisons, 
spoken by the scheming and 
manipulative Marquise de Mer-
teuil, played by Glenn Close, in 
which she contemptuously refers to a young 
man, saying: “He is an intellectual, and like 
most intellectuals, intensely stupid.”  I some-
times wonder if that description could be 
fairly applied to pharmacists. It’s a pretty 
safe bet that a lot of us are intellectual, or at 
the very least have an exam-measurable in-
telligence. The open question is whether or 
not we are stupid, or continually behave like 
we might be.
When it comes down to it, pharmacy is 
a service industry. The same can be said of 
most professions — there’s no fundamen-
tal difference between a GP and a window-
cleaner. So let’s take a look at the street-smarts 
used by barbers back when the VAT rate on 
As a profession, are pharmacists 
dim-witted or do we just do 
a good impression of stupid 
people when it comes to 
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Fintan Moore graduated 
as a pharmacist in 1990 
from TCD and currently runs 
a pharmacy in Clondalkin. 




haircuts changed from 9 per cent to 13.5 per 
cent. My haircuts before the VAT change used 
to cost about €11. Given that cutting my hair 
just involves running a number 3 blade over 
the few relevant parts of my skull, the barber 
was doing pretty well on €11. When the Gov-
ernment changed the VAT rate up by 4.5 per 
cent, the cost of a haircut should have gone 
up by less than 50 cent, but instead it jumped 
to €14. Coincidentally, other barbers in the 
area also hiked prices by similar amounts. So 
the cover story provided by the Government 
let them all become more profitable.
In theory, pharmacists are more intelli-
gent than barbers. If you wanted a Sudoku 
solved or a cryptic crossword filled in, I reck-
on the average pharmacist would be quicker 
than the average scissor-snipper. But would 
we have the brains to pull off a comparable 
stroke to make us more money for the same 
amount of work? Not likely, based on perfor-
mance to date, especially given our willing-
ness to do ever-increasing amounts of work 
while reducing prices. Look at our track re-
cord on FMD scanning. We’ve had to fork-
out money on hardware, as well as the ongo-
ing cost to the various companies we register 
with. But that’s actually the least of it, when 
you measure the workload cost.
Let’s do a back-of-envelope calcula-
tion, assuming a pharmacy is doing 4,000 
items a month. Each scan takes probably a 
minimum of 10 seconds when you factor-in 
bringing every pack to the scanner, twirl-
ing the box to find the bar-code, etc. That’s 
40,000 seconds a month, or 480,000 seconds 
a year. That is 133 hours, which is more than 
three working weeks of productivity lost per 
annum.  You can do your own maths on how 
you put a financial price on that loss, but I 
reckon that to get back to break-even would 
require a 30 cent increase on every private 
prescription. Yet instead of price increases, 
whenever I look around, all I see are more 
pharmacies advertising ever-decreasing 
prices in some kind of frenzy to presumably 
gain ‘volume’.  Maybe I’m the stupid one, but 
you can be the busiest person in town if you 
work for nothing. At least my local barber is 
smart enough to cut hair instead of prices.
BLISTERING COMMENTARY
Notwithstanding our profession absorbing 
the cost of FMD compliance rather than hav-
ing the sense to pass it on to the public, there 
may be glimmers of hope that we are starting 
to realise that any proper service needs to be 
paid for by somebody. I’m reliably informed 
that the Joe Duffy show recently had callers 
complaining about having to pay to for their 
medication to be blister-packed. Nothing 
could induce me to listen to the show, but 
apparently the usual confusion reigned as 
to what could, would or should be paid by 
the HSE when it comes to phased dispens-
ing and/or blister-packing. The good news 
about all this is the fact that enough phar-
macists are charging for a service instead of 
doing it for nothing, in sufficient numbers 
to be a Joe Duffy item. So the question for 
the pharmacists who still aren’t charging is, 
‘why not?’ If the guy down the road from you 
is doing it, then you might as well too. If you 
lose the odd patient, you’ll still be making 
the same money overall, with less of a work-
load. And the people you are still serving will 
be the ones who appreciate what you’re do-
ing enough to respect it by paying for it.
YELLOW-PACK HEALTH SERVICE
Has anybody ever told the HSE employees 
who work in the PCRS that there are only 
12 months in a year? I merely ask because 
another envelope containing 12 yellow 
bags for paperwork was delivered by cou-
rier recently, which means that I now have 
enough bags for about the next four years. 
If even half of the pharmacies in the coun-
try got the same unnecessary delivery, then 
the expense to the HSE was probably about 
€10,000. The waste involved in this may be 
relatively minor in the greater scheme of 
things, but it is symptomatic of a bureau-
cracy that is unreformed, despite supposed 
improved productivity and reform. The 
shelving of proposed recent cuts to phar-
macy was welcome, but it doesn’t look like 
the HSE will react by using its existing funds 
any more efficiently. ●
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Let’s talk 
about dying
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The subject of death and 
dying should not be taboo 
and there needs to be more 
honesty around the topic 
from healthcare professionals, 
writes Terry Maguire
People seldom, if ever, die at con-venient times. Edith was no excep-tion, yet she would have been an-noyed had she thought her demise, 
when it eventually happened, would incon-
venience anyone, never mind me, whom 
she didn’t know. Her daughter, a close work 
colleague, meant I was duty-bound to attend 
her memorial service at the crematorium and 
it was an irony that the largely unplanned 
memorial at mid-day on Wednesday clashed 
with a long-planned training event on pal-
liative care. Edith, diagnosed with cancer, 
was spared a prolonged debilitating illness, 
dying precisely one week later, having re-
fused all interventions. The benefits of a swift 
death, painful as it was for the family, soothed 
their loss. At the Humanist ceremony before 
the coffin was lowered into the furnace, her 
daughter bravely recounted stories of her 
many stunning talents but accepted that she 
was now gone, sad as it was.
Edith’s commendable stoicism, and that 
of her family, was in complete contrast to 
a family I dealt with the previous day. They 
had been told, in what seemed a masterfully 
ambiguous and roundabout way, that their 
84-year-old mother, let’s call her ‘Mary’, was 
dying. Such was the confusion that the GP 
spread, the family were convinced mother 
was on the road to recovery. The GP’s con-
versation was nuanced and conditional to 
the point of being pointless. The GP’s aim, 
as was his professional responsibility, was to 
inform the family at this most poignant and 
important of times that their mother was fin-
ished but in his timidity, he failed miserably.
When the eldest sibling told me the good 
news that mother was on the mend, I cau-
tioned her enthusiasm, only to be strictly ad-
monished. When she started palliative care 
treatment two weeks later, I received a tear-
ful apology that was accepted with a caring 
hug — not politically correct but justified, 
given my service of over 30 years to Mary.
Death, for most, remains such a taboo. 
We just cannot have that conversation, so 
impressed are we that all can be fixed by the 
miracles of modern medicine. So heavily 
invested have national health services and 
politicians become in addressing sickness 
that it seems almost heresy to suggest that 
we can’t cure everything, which of course we 
can’t — unless we use cannabis oil! 
In the modern era, we live such safe lives 
that most of us live long enough to reach the 
end of our natural lives, rather than get eaten 
by a wolf, speared by a savage or killed by an 
exploding shell. We are so good at avoiding 
sudden death that eventually our batter-
ies run down, the wheels come off and the 
plumbing leaks dangerously. We transform 
from productive, sentient individuals to 
hopeless and helpless masses of bones and 
flesh.
Palliative care is not new and has been 
used for terminal cancer patient for decades. 
What is newer is its application to those with 
terminal conditions — heart failure, COPD, 
renal failure, dementia and neurological 
conditions.
Unlike cancers, these conditions do not have 
the cliff off which most cancer patients fall and 
death’s timeline is easily predicable. Rather, 
the journey to death is a slog of minimal gra-
dient, with pot-holes of more rapid decline 
from which the patient emerges to rally, to the 
amazement of family and physicians. This is 
never the road to recovery and there needs to 
be wider recognition of this natural fact.
Of the 15,000 deaths in Northern Ireland 
each year, 11,000 have palliative care needs. 
Where most individuals and families want 
deaths to happen at home, the vast majority 
happen in hospital, and in spite of efforts to 
support more home deaths, in our ‘End-of-
Life Strategy’, little has changed since 2006 
in terms of the place we make our appoint-
ments with death. 
To support our final journey, most of the 
UK regions initially adopted the ‘Liverpool 
Pathway’, which defined what should be 
done and when. There was a backlash from 
families who felt that this approach was too 
callous and perhaps there was too much fo-
cus on death, so it was abandoned. 
Medicines for most chronic long-term 
conditions need to be withdrawn when 
death is imminent, but there is little evi-
dence that this is happening. Certainly most 
drugs, statins, endocrines, respiratory, etc, 
can and should be withdrawn, administer-
ing only those that specifically support pal-
liative care. Antibiotics are a cause of par-
ticular passion. Giving an antibiotic while 
the patient is clearly dying may stop or delay 
the process of dying, leaving the end to an-
other time but with no other material benefit 
to the patient. 
Above all, when death is a few days away, 
there is a need to withdraw food, then fluids, 
and provide support and comfort only as-
needed. Too many family members inter-
vene and insist on oxygen therapy, PEG tube 
feeding and then saline drips. While these 
interventions are largely pointless, they are 
not sufficiently challenged by medical staff 
who seem to go with the notion that some-
thing positive should be done.
Both Edith and Mary are now gone. Each 
family has a different view of the palliative 
care process. Edith’s family were spared a 
long, lingering death, but Mary’s was not and 
the longer it went on, the more futile the in-
terventions being tried were and rather than 
being caring were, in a distorted and unin-
tentional way, cruel. 
As a society, we need to talk more about 
death and dying and we need to do it more 
generally, so that when a family is faced with 
the huge challenges of the last few weeks of 
someone’s life, they can make decisions from 
a position of caring, informed understanding, 
rather than cruel emotional ignorance. ●
Terry Maguire owns two pharmacies 
in Belfast. He is an honorary senior 
lecturer at the School of Pharmacy, 
Queen’s University of Belfast. His research 
interests include the contribution of 
community pharmacy to improving 
public health.
CONTRIBUTOR INFORMATION
Palliative care is not 
new and has been used for 
terminal cancer patients for 
decades
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Controversy has sur-rounded e-cigarettes since they were first appeared in 2006. Are 
they a valuable aid for those trying 
to quit smoking, or are they just 
another way of hooking young 
people on nicotine? These are 
just two of the questions this 
new technology has posed. 
Some believe they should be 
regulated as medical devices 
by the HPRA, while others 
favour the present unregu-
lated free-for-all, on com-
mercial grounds. 
The range of products is 
bewildering, as is the ter-
minology used. A variety 
of names exist, includ-
ing ‘e-cigarettes’, ‘e-
cigs’, ‘mods’, ‘vape pens’, 
‘vapes’, and even ‘elec-
tronic nicotine deliv-
ery systems’. Some look 
like cigarettes, cigars 
and pipes, while oth-
ers resemble pens and 
USB sticks with refillable 
cartridges or pods. The 
latter are the dominant 
product in the States, ac-
counting for 70 per cent of 
sales. They work by using a 
battery-powered metal re-
sistance coil to heat nicotine, 
flavourings, propylene glycol and 
Dr Des Corrigan 
writes on the current 
controversy in 
e-cigarettes and 
breaks down some 
of the terminology in 
‘cannavaping’ 
and its link to ‘Earwax’, ‘BHO’ and ‘Dabbing’
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vegetable glycerine in liquid form to pro-
duce an aerosol that users inhale into their 
lungs. That aerosol can contain (apart from 
the nicotine) volatile carbonyls, furans and 
reactive oxygen species, carcinogens, heavy 
metals (nickel, tin and lead), as well as ultra-
fine particulate matter. A key flavouring is 
diacetyl, the inhalation of which is known to 
cause a form of bronchiolitis called ‘popcorn 
worker’s lung’. Since plant tissue is not being 
burned, as in a cigarette, many of the harm-
ful pyrolysis products from either tobacco 
leaf or cannabis herb will not be produced. 
Therefore, a case can be made that e-ciga-
rettes may be less harmful to the lung than 
conventional cigarettes and certainly Public 
Health England is of that view.
However, proponents of these devices 
may lose sight of the fact that nicotine is still 
a highly-addictive compound that can be 
embryotoxic, may harm adolescent brain 
development and is a recognised poison. 
Two RCTs found that nicotine-containing 
e-cigarettes can help smokers quit over 
the long term when compared to placebo 
non-nicotine-containing devices. It is vital, 
however, that those quitting use e-cigarettes 
alone and that they do not fall into the trap 
of becoming ‘dual users’, ie, smoking regular 
cigarettes and also using e-cigarettes. In the 
US, electronic cigarettes are most commonly 
used by high-school students, raising con-
cerns about the impact on their developing 
brains and the risk of their becoming ad-
dicted to nicotine. The high level of vaping 
by young people has reversed progress in the 
decline in tobacco use by that age cohort. 
The controversy over these devices has 
intensified in recent months because of the 
emergence of what is now called EVALI in the 
US. The acronym stands for E Vaping Associ-
ated Lung Injury. At the time of writing, the 
Centres for Disease Control and Prevention 
(CDC) has reported 2,290 cases of ‘vape lung 
injury’, including 47 deaths. Cases have been 
reported from 49 states (Alaska is the excep-
tion) and involve mostly young white males, 
all with a history of vaping. Out of 867 pa-
tients for whom data is available, 86 per cent 
reported use of THC, 64 per cent nicotine, 52 
per cent both THC and nicotine, 34 per cent 
only THC, and 11 per cent only nicotine. The 
THC-containing products were obtained 
particularly from street sources, friends, fam-
ily members or illicit dealers. When samples 
were available for testing by the FDA, most 
were positive for THC but until recently, no 
one compound or ingredient had emerged 
as the cause of the injury to the lungs. Bron-
choscopy samples from 29 patients were ex-
amined and vitamin E acetate identified in 
all samples. This is used in some THC-con-
taining products to thicken the oil. Obviously, 
vitamin E acetate does not cause respiratory 
problems if taken orally or applied topically, 
but it is known that if it is inhaled, it may af-
fect the lungs. Frantic efforts are underway 
to establish the exact cause of ‘vape lung’ 
and there has been a huge drop in sales and 
calls by politicians and health professionals, 
including the American Medical Association 
for bans on the advertising and sale of e-ciga-
rettes. Not surprisingly, these calls have been 
matched by industry lobbying to prevent any 
attempt to curtail their profiteering.
 Much of the THC consumed in what is 
called ‘cannavaping’ is in the form of oily 
solutions in refillable cartridges, although 
some was used by ‘dabbing’ or ‘dripping’ of 
a THC-rich cannabis concentrate directly 
onto the heated coil of the e-cigarette. ‘Dab-
bing’ is a relatively new method of drug use 
that emerged from the development of ‘con-
centrates’ by the now-legal cannabis indus-
try. These concentrates were originally sup-
posed to be used to manufacture ‘edibles’ 
— cannabis products for medicinal use de-
signed to be eaten as confectionery or drunk 
in beverages (beers or soft drinks) by those 
wishing to avoid smoking the drug. Some 
concentrates are made using dry processing 
methods, such as dry ice. 
Water-based methods provide what is 
known as ‘bubble hash’. Although organic 
solvents such as ethanol or acetone can be 
used, most commercial and indeed amateur 
concentrates are processed using a liquid 
gas, such as pressurised butane. Some phar-
maceutical-grade extracts use supercritical 
fluid extraction technology with liquid car-
bon dioxide because no solvent resides re-
main after it evaporates off.
 Butane is particularly popular, giving rise 
to what is termed BHO (butane hash oil). 
Evaporation of the gas leaves a brown or yel-
lowy-white solid with a low melting point. In 
slang terms, this is called ‘ear wax’, ‘crumble’, 
‘honeycomb’, ‘shatter’ or ‘budder’, depend-
ing on its consistency and physical appear-
ance. Such concentrates can have a THC 
content ranging from 69-to-95 per cent, de-
pending on the potency of the starting can-
nabis plant material. Samples of BHO tested 
in the UK in 2016 gave THC contents ranging 
from 73-to-83 per cent with less than 1 per 
cent of CBD. To put that into context, herbal 
cannabis from the 1960s through to the late 
1990s had between 1-and-3 per cent THC 
and hash had between 3 and 10 per cent.
Until the emergence of ‘cannavaping’, 
dabbing involved the application of a small 
amount of concentrate (a ‘dab’) to a nail made 
of titanium, which was then flash-vapourised 
with a butane flame, such as the popular 
crème brûlée torch. The vapour was then in-
haled in a single puff through a water pipe. 
More THC is absorbed by ‘dabbing’ than by 
smoking marijuana flower buds (76 per cent 
vs 27 per cent). It is also absorbed much more 
quickly (seconds vs minutes), producing a 
more intense euphoric high. Swiss research-
ers noted that as a result, dabbing provides 
an easier way of quickly consuming massive 
doses of THC that is more likely to lead to 
tolerance and withdrawal symptoms. A 2017 
study in Drug and Alcohol Dependence of 121 
recent BHO users reported higher levels of 
physical dependence, impaired control, aca-
demic and occupational problems.
In the meantime, the CDC in the States has 
advised against any vaping of THC-contain-
ing products at present. Even for those who 
are vaping only nicotine, caution is advised 
because stronger evidence is needed before 
any definitive statement can be made as to 
whether e-cigarettes are effective in helping 
smokers quit. ●
CONTRIBUTOR INFORMATION
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I am writing this noting that my previous open letter to our Minister for Health was somewhat redundant by the time it was published. I did send it to him; 
incidentally, he chose to acknowledge its re-
ceipt on the day I write this. About a 75 per 
cent acknowledgement of correspondence 
rate from public representatives is perhaps 
reasonable. I have come to the conclusion, 
having been on the receiving end of an oc-
casional snubbing, or having been ignored, 
that it is kinder to acknowledge, making a 
modest allowance for occasionally forget-
ting to, of course. 
Too many curricula vitae have ended up in 
the bin over the years without me acknowl-
edging their receipt and thanking the person 
for their interest in our company. Too many 
company representatives and sales people 
have got a response that was curt and igno-
rant, perhaps on foot of my own stress levels 
and energy resources. I understand, since 
‘it’s business’ and all that, but there really is 
no need to be so rude in most cases. 
Is it the Buddhists who suggest that kind-
ness and compassion are everything. Now, 
that’s a noble aspiration for the new year 
ahead. I know that I, for one, will struggle. 
A VISION FOR THE FUTURE
We didn’t receive the cuts that we could have 
before Christmas under FEMPI regulations, 
with the promise of a new “fit-for-purpose” 
pharmacy contract being developed this 
year. We had, however, circa €28,000 in 
phased prescription fees cut in our pharma-
cy business, which is highly significant on 
our modest turnover. This unexplained can-
celling of patient eligibility without engage-
ment or explanation appears to have gone 
under the radar completely for our politi-
cians and our Minister. 
“We have the people to deliver this”, one 
colleague had posted on a pharmacist so-
cial medium in relation to new contract 
negotiations, and this got me thinking. 
Credit whom or what you will for this pre-
Christmas achievement, or rather a preven-
Ultan Molloy looks at the factors 
that will be necessary in 2020 to 
bring the profession forward and 
reviews his correspondence with the 
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tion of a further drain on community phar-
macy resources, but we have little to show 
in terms of successes in the sector over the 
last 10-year period. A flu vaccination service 
as a professional service offers a glimmer of 
hope, although it continues to be a financial 
loss-leader given the cost of training, the 
cost of providing the service, and the poor 
remuneration paid following negotiations 
with the PCRS. Professional services should 
not be a loss-leader, so don’t even go there 
with me, in case that’s your retort. If nothing 
is sacred, then the sector is destined to the 
same fate as fast-moving consumer goods. 
As much (medicine) as you can, as cheap as 
you can and as fast as you can. 
Have we a situation where the profession 
is represented at the most senior executive 
levels in the Government? The absence of a 
Chief Pharmacy Officer representing the in-
terests of pharmacists daily at Government 
level speaks volumes about the value seen in 
having that position. 
We have a single representative body for 
community pharmacists at present. Noting 
that previous behaviour is the best predic-
tor of future behaviour, we can ask, does it 
have the capability, capacity and culture to 
deliver a robust new fit-for-purpose contract 
for community pharmacy, and the patients 
and customers it serves? We can ask, thanks 
to Beckhard, are there clear goals, roles, in-
terpersonal relationships and processes in 
place in-house in order to deliver for us? 
We can ask, is there a culture of high perfor-
mance where results follow from account-
ability, commitment and trust based on a 
culture of healthy, respectful conflict?
Of course, what we wouldn’t want in such 
an organisation is in-fighting at executive 
level, a culture of cronyism, an acceptance 
of mediocre performance in key roles, and 
an apparent unwillingness to hold people to 
account for poor performance. We wouldn’t 
want a metaphorical ‘circle-jerk’, a reluctance 
to listen to and objectively evaluate dissent-
ing opinions, or the group-think, such as in 
Anglo Irish Bank that contributed signifi-
cantly to our previous economic crisis. We 
certainly wouldn’t want a situation where 
pharmacists could be seen as a privileged, 
tuxedoed, chicken-dinner brigade, primarily 
concerned with their business interests over 
that of patient and customer care, on a win-
win-win basis. We wouldn’t want a body that 
offers much in terms of photoshoots and 
press for the media, and much less in terms 
of results for the community pharmacists 
who pay in order to have their interests pro-
fessionally, responsibly and diligently repre-
sented. 
We would want appropriate corporate 
governance and leadership. We would want 
a board that is holding the CEO and their 
executive team to account for their perfor-
mance against set ambitious targets and 
metrics. We would want to see a demon-
strated ability to build relationships, com-
municate effectively and influence policy 
at the most senior levels of Government. 
We would want to see an understanding of 
the perspectives of all the key shareholders 
clearly demonstrated, and those stakehold-
ers engaging on foot of this. We would want 
the value of pharmacists as healthcare pro-
fessionals and experts in the safe and effec-
tive use of medicines communicated clearly, 
consistently and concisely at every available 
opportunity. 
‘GOOD IS THE ENEMY OF GREAT’
Harry Hughes, Chair of the Hughes Group 
based out of Westport and employing 4,500 
people worldwide and turning over €260 mil-
lion, said their culture embraces a philosophy 
of “good” being “the enemy of great”. Where 
does that leave ‘average’, I would ask? To any-
one who suggests, ‘well, things could have be 
much worse if I/we/they weren’t there’, I ask, 
would things have be significantly better if 
someone else was there instead? 
To those of you who rest assured of your 
own brilliance, then maybe consider the 
foundation for that opinion (see ‘circle-jerk’, 
‘group-think’ etc above). To those of you 
who spend much of their time dismantling 
and finding fault with yourself, and your own 
opinion, then maybe it’s time to step up and 
back yourself. 
A FIT-FOR-PURPOSE CONTRACT
I’ve included three of the paragraphs below 
from the Minister’s correspondence for us to 
consider starting into 2020. 
“The Minister recognises the significant 
role community pharmacists play in the de-
livery of patient care and the potential for 
this role to be developed further in the con-
text of health service reform and modernisa-
tion. Community pharmacy is recognised as 
the most accessible element of our health 
service, with an unequalled reach in terms 
of patient contact and access.
“The comprehensive review of the phar-
macy contract in 2020 will address the role to 
be played by community pharmacy in the con-
text of Sláintecare. It will consider all aspects of 
pharmacy service provision, including deliv-
ery of a multidisciplinary model of service de-
livery for patients, ensuring clarity of roles and 
achieving optimum value for money. 
“However, any publicly-funded pharmacy 
service expansion should address unmet 
public healthcare needs, improve access to 
existing public health services or provide 
better value for money or patient outcomes. 
Accordingly, any measures to be considered 
must be evidence-based.”
So meeting unmet patient needs, improv-
ing access to present services, better value 
for money and better patient outcomes. Evi-
dence for these things, please? Anyone work-
ing in a community pharmacy has a sense of 
the value the service brings for patient care. 
Pilot trials in Ireland, evidence on initiatives 
through pharmacy from other jurisdictions 
and the significant impact of the vaccination 
service on immunisation rates appear not to 
have addressed the Minister’s concerns to 
date. Is it therefore a case of ‘There are none 
so blind as those who will not see’, as quoted 
to me by a colleague recently, or are there 
other reasons? Could it be credibility, rela-
tionships, communication skills, influencing 
skills, insufficient evidence, or another vari-
able in the mix, as best efforts to date have 
clearly not been good enough. 
Good luck to all of us reading this for 2020 
and beyond. We will need good luck, and 
much more than just good luck, if the future 
is to play out positively for ourselves, our pa-
tients, our customers and our communities. ●
Ultan Molloy is a business and 
professional performance coach, 
pharmacist, facilitator and development 
specialist. He works with other 
pharmacists, business owners and third 
parties to develop business strategies. 
Ultan can be contacted on 086 1693343.
CONTRIBUTOR INFORMATION
“I quit smoking for her”
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Help smokers quit with an unbeatable 
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*Provides significant improvements in quit rates vs patch alone. Stead LF et al. 2012 Nicotine replacement therapy for smoking cessation, Cochrane Library.
NiQuitin CLEAR 24 hrs transdermal patches are indicated for the relief of nicotine withdrawal symptoms including cravings as an aid to smoking cessation. Indicated in adults and adolescents aged 12 years 
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children under 12 years and occasional smokers. Precaution: Supervise use if hospitalised for MI, severe dysrhythmia or CVA, if haemodynamically unstable.  Use with caution in patients with active 
oesophagitis, oral and pharyngeal inflammation, gastritis, peptic ulcers, GI disturbances, susceptible to angioedema, urticaria, renal/hepatic impairment, hyperthyroidism, diabeties, phaeochromocytoma, 
seizures & epilepsy. Discontinue if severe persistent skin rash. Pregnancy and lactation: Oral formats preferable to patches unless nauseous. Remove patches at bedtime. Side effects: Transient rash, 
itching, burning, tingling, numbness, swelling, localised pain urticaria, hypersensitivity reactions. headache, dizziness, tremor, sleep disorders, nervousness, palpitations, tachycardia, dyspnoea, pharyngitis, 
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medicines.ie/medicine/12138/SPC/NiQuitin+CLEAR+21+mg+24+hours+transdermal+patch/  NiQuitin Mini 1.5mg/4mg Mint Lozenges are used for the treatment of tobacco dependence by relief of 
nicotine withdrawal symptoms and cravings. Indicated in adults and adolescents aged 12 years and over. NiQuitin Mini 1.5 mg are suitable for those who smoke who smoke 20 cigarettes or less a day. 
NiQuitin Mini 4 mg are suitable for smokers who smoke more than 20 cigarettes a day. Place a lozenge in the mouth whenever there is an urge to smoke, allow to dissolve completely. Do not chew or swallow 
whole. Abrupt cessation: Use a lozenge whenever there is an urge to smoke, maximum of 15 lozenges a day. Continue for up to 6 weeks, then gradually reduce lozenge use. Gradual cessation: Use lozenges 
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diseases.1 It is 
the only legal 
drug product that kills many 
of its users when used exactly 
as intended by manufacturers. 
People who smoke cigarettes 
have a higher chance of devel-
oping:2
• Breathing problems: 
Nearly 80 per cent of deaths 
from COPD are attributable 
to smoking.
• Cancer: Lung, throat and 
mouth especially. Ninety 
percent of lung cancers, 
and at least 30 per cent of 
all cancer deaths, are at-
tributable to smoking.3
• Cardiovascular disease: 
Myocardial infarction, 
coronary artery disease, 
hypertension, peripheral 
vascular disease.
• Eye problems, ie, cataracts.
• Gastrointestinal issues, ie, 
peptic ulcers and inflam-
matory bowel disease.2
• Impaired fertility, im-
potence, spontaneous 
abortions; also, ectopic 
pregnancies.




Most of the harm from smok-
ing is caused by the burning of 
tobacco, as opposed to nicotine 
itself. Cigarette smoke contains 
over 4,000 chemicals (Figure 1) 
— this includes approximately 
69 chemicals that are well-es-
tablished carcinogens, and over 
400 other toxins.
NICOTINE ADDICTION
Nicotine is a highly-addictive 
compound. Smoking cigarettes, 
ie, administration through 
the lung, provides almost 
instant absorption, permitting 
nicotine to enter the brain in 
six seconds. The speed and ef-
ficiency of this route reinforces 
self-administration of nicotine.2 
The pharmacological basis of 
nicotine addiction is a due to 
positive reinforcement: En-
hancement of mood, improved 
functioning, such as better con-
centration and reaction time; 
also, avoidance of withdrawal 
symptoms.
 Smoking is associated with 
a pleasurable experience and 
a sense of satisfaction. This is 
caused by stimulation of the 
nicotinic cholinergic receptors 
in the brain, which releases 
neurotransmitters includ-
ing dopamine. The release of 
multiple other neurotransmit-
ters such as noradrenaline, 
acetylcholine, serotonin, 
γ-aminobutyric acid, gluta-
Tobacco use is the 
leading cause of 
preventable death 
in Ireland but the 
rewards of quitting are 
huge, writes Donna 
Cosgrove PhD MPSI
Figure 1: Cigarette smoke contains a number of carcinogens and toxins1
SMOKING
TOBACCO
Donna Cosgrove PhD MPSI
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mate, and endorphins lead to 
the arousal, mood modulation, 
performance enhancement, 
analgesic, and weight-loss ef-
fects associated with smoking.5 
Tolerance and desensitisation 
develop with repeated use4 due 
to an increase in the number 
of binding sites present on 
nicotinic receptors. This means 
that higher doses of nicotine 
are then required to achieve the 
same level of stimulation. When 
these desensitised receptors 
again become responsive in 
times of prolonged abstinence, 
craving and withdrawal symp-
toms such as anxiety and stress 
then manifest, ie, after waking 
up from an overnight sleep. 
Smoking again alleviates crav-
ings and withdrawal symptoms, 
which provides positive rein-
forcement, further encouraging 
the smoking habit. The avoid-
ance of withdrawal symptoms 
becomes a reason in itself to 
smoke. With regular smoking, 
certain cues may be associ-
ated with the habit: The mood 
modulation and arousal caused 
by nicotine may eventually be 
associated with the actions of, 
ie, rolling a cigarette, lighting 
it, and physical movement of 
smoking itself, separate to the 
direct pharmacological effect. 
The pairing of a significant stim-
ulus or action like smoking or 
buying cigarettes with a certain 
signal like relief of anxiety will 
result in a conditioned response 




Nicotine replacement therapy 
(NRT) helps reduce withdrawal 
symptoms by replacing the 
nicotine from cigarettes with 
nicotine from alternative, safer 
forms such as gum, a transder-
mal patch, nasal spray, inhaler 
or sublingual tablets/lozenges. 
Studies indicate that all these 
types of delivery systems help 
people increase their chances 
of successfully stopping. A 
systematic review of 150 trials 
comparing NRT to placebo 
found that NRT increased quit-
ting rates by about 50-to-70 per 
cent.6 No overall difference in 
effectiveness between the dif-
ferent forms of NRT was identi-
fied. How-
ever, combining 
a sustained delivery 
method, ie, the nicotine 
patch, with an additional rapid 
delivery preparation, such as 
gum, spray or lozenge, is more 
effective than use of one type of 
NRT by itself. When discontinu-
ing the patch, abrupt withdraw-
al did not give rise to any differ-
ence in outcome compared to 
patch tapering. Furthermore, 
no significant difference in 
efficacy was observed between 
the 16-hour patch worn during 
waking hours only and 24-hour 
patch. In general, the side-
effects from NRT use are mild 
and include hiccups, jaw pain, 
orodental problems (from the 
gum); and local irritation at the 
site of the patch. There is no 
association between NRT and 
an increased 
risk of adverse cardiovascular 
events in smokers with a history 
of cardiovascular disease.
Other smoking cessation 
medication available on pre-
scription, such as bupropion 
(Zyban), provides a selective 
inhibitor of the neuronal 
re-uptake of catecholamines 
(noradrenaline and dopamine). 
When NRT use was compared 
with bupropion use, they were 
found to be equally effective. In 
contrast, a study found vareni-
cline (Champix) to be superior 
to bupropion and NRT as a 
smoking cessation aid for both 
short and long term.7 Vareni-
cline acts as a partial agonist 
Upon smoking cessation, 
the following benefits 
are noticeable:1
After 20 minutes 
blood pressure and pulse 
rate decrease to normal 
range. Circulation in hands 
and feet improves.
After eight hours 
blood oxygenation 
levels return to 
normal and the risk of 
myocardial infarction 
starts to decrease.
After 24 hours 
poisonous carbon monoxide 
is eliminated from the body. 
The lungs start to clear out 
mucus and other debris.
After 48 hours 
nicotine can no longer 
be detected in the 
body. Senses of taste 
and smell improve.
After 72 hours 
breathing improves and 
becomes easier as the 
bronchial tubes relax, and 
energy levels increase.
After two weeks 
circulation improves further, 
contributing to easier 
walking and other exercise.
After three-to-nine months 
respiratory issues such 
as coughing, shortness 
of breath and wheezing 
substantially reduce.
After five years 
the risk of myocardial 
infarction decreases to 
that of a non-smoker.
Benefits of smoking cessation
*Based on 2 x 1mg dose 
Nicorette QuickMist1 mg/spray, oromucosal spray, solution. Composition: One spray delivers 1 mg nicotine in 0.07 ml solution. 1 ml solution contains 13.6 mg nicotine. Excipient with known effect:  Ethanol (less than 100 mg of ethanol/spray). Propylene glycol, Butylated hy-
droxytoluene. Pharmaceutical form: Oromucosal spray, solution. A clear to weakly opalescent, colourless to yellow solution. Indications: For the treatment of tobacco dependence in adults by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt. Permanent 
cessation of tobacco use is the eventual objective. Nicorette QuickMist should preferably be used in conjunction with a behavioral support program. Dosage: Subjects should stop smoking completely during the course of treatment with Nicorette QuickMist. Adults and Elderly: The 
following chart lists the recommended usage schedule for the oromucosal spray during full treatment (Step I) and during tapering (Step II and Step III). Up to 4 sprays per hour may be used. Do not exceed 2 sprays per dosing episode and do not exceed 64 sprays (4 sprays per hour, 
over 16 hours) in any 24-hour period. Step I: Weeks 1-6: Use 1 or 2 sprays when cigarettes normally would have been smoked or if cravings emerge. If after a single spray cravings are not controlled within a few minutes, a second spray should be used. If 2 sprays are required, 
future doses may be delivered as 2 consecutive sprays. Most smokers will require 1-2 sprays every 30 minutes to 1 hour.  Step II: Weeks 7-9: Start reducing the number of sprays per day. By the end of week 9 subjects should be using HALF the average number of sprays per day 
that was used in Step I. Step III: Weeks 10-12: Continue reducing the number of sprays per day so that subjects are not using more than 4 sprays per day during week 12. When subjects have reduced to 2-4 sprays per day, oromucosal spray use should be discontinued. To help 
stay smoke free after Step III, subjects may continue to use the oromucosal spray in situations when they are strongly tempted to smoke. One spray may be used in situations where there is an urge to smoke, with a second spray if one spray does not help within a few minutes. No 
more than four sprays per day should be used during this period.  Regular use of the oromucosal spray beyond 6 months is generally not recommended. Some ex-smokers may need treatment with the oromucosal spray longer to avoid returning to smoking. Any remaining oromucosal 
spray should be retained to be used in the event of sudden cravings. Paediatric population: Do not administer this medicine to persons under 18 years of age. There is no experience of treating adolescents under the age of 18 with this medicine. Method of administration: After 
priming, point the spray nozzle as close to the open mouth as possible.  Press firmly the top of the dispenser and release one spray into the mouth, avoiding the lips. Subjects should not inhale while spraying to avoid getting spray into the respiratory tract. For best results, do not 
swallow for a few seconds after spraying.  Subjects should not eat or drink when administering the oromucosal spray. Behavioural therapy advice and support will normally improve the success rate. Contraindications: Hypersensitivity to nicotine or to any of the excipients. Children 
under the age of 18 years. Those who have never smoked. Special warnings and precautions for use: This medicine should not be used by non-smokers. The benefits of quitting smoking outweigh any risks associated with correctly administered nicotine replacement therapy 
(NRT).  A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions: Cardiovascular disease: Dependent smokers with a recent myocardial infarction, unstable or worsening angina including Prinzmetal’s angina, severe 
cardiac arrhythmias,  recent cerebrovascular accident and/or who suffer with uncontrolled hypertension should be encouraged to stop smoking with non-pharmacological interventions (such as counselling). If this fails, the oromucosal spray may be considered but as data on safety 
in this patient group are limited, initiation should only be under close medical supervision. Diabetes Mellitus. Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when smoking is stopped and NRT is initiated as reduction in 
nicotine induced catecholamine release can affect carbohydrate metabolism.  Allergic reactions: Susceptibility to angioedema and urticaria. Renal and hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as 
the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects. Phaeochromocytoma and uncontrolled hyperthyroidism: Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release 
of catecholamines. Gastrointestinal Disease: Nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastric or peptic ulcers and NRT preparations should be used with caution in these conditions. Paediatric population: Danger in children: Doses of nicotine toler-
ated by smokers can produce severe toxicity in children that may be fatal. Products containing nicotine should not be left where they may be handled or ingested by children. Transferred dependence: Transferred dependence can occur but is both less harmful and easier to break 
than smoking dependence.  Stopping smoking: Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs metabolised by CYP 1A2 (and possibly by CYP 1A1). When a smoker stops smoking, this may result in slower metabolism and a consequent rise in 
blood levels of such drugs. This is of potential clinical importance for products with a narrow therapeutic window, e.g. theophylline, tacrine, clozapine and ropinirole. The plasma concentration of other medicinal products metabolised in part by CYP1A2 e.g. imipramine, olanzapine, 
clomipramine and fluvoxamine may also increase on cessation of smoking, although data to support this are lacking and the possible clinical significance of this effect for these drugs is unknown. Limited data indicate that the metabolism of flecainide and pentazocine may also be 
induced by smoking.  Excipients: The oromucosal spray contains small amounts of ethanol (alcohol), less than 100 mg per dose (1 or 2 sprays). This medicinal product contains less than 1 mmol sodium (23 mg) per spray, i.e. essentially ‘sodium- free’. This medicine contains 12 mg 
propylene glycol in each spray which is equivalent to 150 mg/mL. Due to the presence of butylated hydroxytoluene, Nicorette QuickMist may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes. Care should be taken not to spray the 
eyes whilst administering the oromucosal spray. Undesirable effects: Effects of smoking cessation: Regardless of the means used, a variety of symptoms are known to be associated with quitting habitual tobacco use. These include emotional or cognitive effects such as dysphoria 
or depressed mood; insomnia; irritability, frustration or anger; anxiety; difficulty concentrating, and restlessness or impatience. There may also be physical effects such as decreased heart rate; increased appetite or weight gain, dizziness or presyncopal symptoms, cough, constipa-
tion, gingival bleeding or apthous ulceration, or nasopharyngitis. In addition, and of clinical significance, nicotine cravings may result in profound urges to smoke. This medicine may cause adverse reactions similar to those associated with nicotine given by other means and these are 
mainly dose-dependent. Allergic reactions such as angioedema, urticaria or anaphylaxis may occur in susceptible individuals. Local adverse effects of administration are similar to those seen with other orally delivered forms. During the first few days of treatment irritation in the mouth 
and throat may be experienced, and hiccups are particularly common. Tolerance is normal with continued use.  Daily collection of data from trial subjects demonstrated that very commonly occurring adverse events were reported with onset in the first 2-3 weeks of use of the 
oromucosal spray, and declined thereafter. Adverse reactions with oromucosal nicotine formulations identified from clinical trials and during post-marketing experience are presented below. The frequency category has been estimated from clinical trials for the adverse reactions 
identified during post-marketing experience. Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from the available data). Immune system disorders Common 
Hypersensitivity Not known Allergic reactions including angioedema and anaphylaxis Psychiatric disorders Uncommon Abnormal dream Nervous system disorders Very common Headache Common Dysgeusia, paraesthesia Eye disorders Not known Blurred vision, lacrimation 
increased Cardiac disorders Uncommon Palpitations, tachycardia Not known Atrial fibrillation Vascular disorders Uncommon Flushing, hypertension Respiratory, thoracic and mediastinal disorders Very common Hiccups, throat irritation Uncommon Bronchospasm, rhinorrea, 
dysphonia, dyspnoea, nasal congestion, oropharyngeal pain, sneezing, throat tightness Gastrointestinal disorders Very common Nausea Common Abdominal pain, dry mouth, diarrhoea, dyspepsia, flatulence, salivary hypersecretion, stomatitis, vomiting Uncommon Eructation, 
gingival bleeding, glossitis, oral mucosal blistering and exfoliation, paraesthesia oral Rare Dysphagia, hypoaesthesia oral, retching Not known Dry throat, gastrointestinal discomfort, lip pain Skin and subcutaneous tissue disorders Uncommon Hyperhidrosis, pruritus, rash, urticar-
ia Not known Erythema General disorders and administration site conditions Common Burning sensation, fatigue Uncommon Asthenia, chest discomfort and pain, malaise. MAH: Johnson & Johnson (Ireland) Limited, Airton Road, Tallaght, Dublin 24, Ireland. PA Number: PA 
330/37/13. Date of revision of text: PA 330/37/13: May 2019. Product not subject to medical prescription. Full prescribing information available upon request.  IRE/NI/19-4006
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at the α4β2 neuronal nicotinic 
acetylcholine receptors. There 
is also evidence for the efficacy 
of nortriptyline and clonidine 
as second-line therapies for 
smoking cessation. 
ELECTRONIC CIGARETTES
The use of electronic cigarettes 
(e-cigarettes) as a smoking aid 
has become increasingly con-
troversial. Although non-com-
bustible tobacco products have 
offered a way for adult smokers 
to move away from more harm-
ful forms of nicotine delivery, it 
is important that these op-
portunities do not come at the 
expense of leading a generation 
of young people towards nico-
tine addiction. Young people 
who have tried e-cigarettes are 
more likely to try combustible 
tobacco products later.
There have been several 
recent newspaper reports based 
on a study by researchers in 
Germany published at the end 
of 2019 in the European Heart 
Journal.8 One report9 describes 
the damage of e-cigarettes to 
brain, heart, lungs and blood 
vessels; another is about the 
Irish Heart Foundation calling 
for a ban on all e-cigarette 
advertising.10 The results of 
the study in question strongly 
indicate that the perceived 
‘safety’ of e-cigarette products 
(compared to tobacco) is not 
warranted. Contributing to the 
drive for this research is the in-
crease in e-cigarette use among 
high school students in the US 
from 1.5 per cent to 20.8 per 
cent between 2011 and 2018. 
In addition, there are ongoing 
investigations on severe pulmo-
nary disease and deaths among 
people using e-cigarettes in the 
US. The authors state that there 
is lack of clarity as to the overall 
population health consequenc-
es of e-cigarette use: A majority 
of available studies provide 
evidence that e-cigarette vaping 
is the ‘lesser of two evils’ when 
compared to tobacco cigarette 
smoking, but considering that 
e-cigarette vaping is associated 
with a decrease in the average 
age of first-time (e)-cigarette 
users, the ‘healthier’ e-cigarette 
profile might easily be negated 
by the higher portion of adoles-
cent users.
In the study,8 experiments 
were performed in mice, 
administering unflavoured e-
cigarette liquids with and with-
out nicotine to determine the 
impact on vascular (endothe-
lial) function. The researchers 
characterised the mechanisms 
behind oxidative stress and 
inflammation, and validated 
findings in human endothelial 
cells and in healthy smokers. 
Results show that in other-
wise healthy smokers (n = 20), 
e-cigarette vapour exposure 
reduced arterial dilation, 
increased blood pressure, and 
increased arterial stiffness. 
This indicates induction of 
endothelial dysfunction by 
e-cigarette vaping. This dys-
function was also identified in 
mice and in human endothe-
lial cells. 
Results show that the act of 
e-cigarette vaporisation adds 
additional toxicity to its com-
ponents. This mechanism has 
been identified by the authors 
to be due to NADPH oxidase 
2 (NOX-2) mediation, which 
induces oxidative stress. Toxic 
compounds including formal-
dehyde, acetaldehyde, butyr-
aldehyde, and acrolein were 
identified in e-cigarette liquid, 
but to much larger extent in 
vapour condensate. 
To examine the toxicity of 
these vapour-enhanced prod-
ucts, cultured human endothe-
lial cells were incubated with 
mixtures of these aldehydes. 
This resulted in concentration-
dependent cell death and 
increased expression of the 
inflammatory marker COX-2. 
Overall, e-cigarette vapour 
exerts a broad negative influ-
ence on the vasculature due, in 
part, to vaporisation-enhanced 
aldehyde generation that acti-
vates NOX-2, leading to oxida-
tive stress, inflammation, and 
endothelial dysfunction.
Much data in this publica-
tion seems to indicate that 
e-cigarette vapour shares many 
of the same adverse vascular 
consequences of traditional 
tobacco smoke. Both the smok-
ing of combustible cigarettes 
and e-cigarettes increase 
oxidative stress and appear to 
degrade blood-brain barrier 
integrity and to induce vascular 
inflammation in endothelium. 
Likewise, both tobacco smoke 
and e-cigarette vapour induce 
cerebrovascular inflammation 
and post-stroke ischaemia/re-
perfusion damage in mice. 
After 10 years, lung cancer 
risk decreases to about half that 
of a smoker.
It has been estimated that 
75-to-85 per cent of people 
who smoke would like to quit 
smoking. Pharmacists in the 
community, often the first 
point of contact with the health 
services, can help by provid-
ing these individuals with 
advice on smoking cessation.11 
As part of the conversation, 
the pharmacist can assess the 
readiness of the individual to 
quit and enquire about previ-
ous attempts. Pharmacists 
should discuss the potential 
withdrawal symptoms follow-
ing smoking cessation (sleep 
disturbance, nausea, head-
ache, dizziness, cough, mouth 
ulcers). These symptoms, along 
with the urge to smoke, can 
lead to relapse. Most withdraw-
al symptoms, however, stop 
after two-to-four weeks, so it 
is especially important for the 
individual to have support dur-
ing this time. The Irish website 
www.quit.ie offers further help 
and information for people 
who want to stop. ●
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A
sthma is a 
long-term con-
dition  that can 
cause a cough, 
wheezing and 
breathlessness. The severity of 
the symptoms varies from person 
to person.
In Ireland, respiratory diseas-
es are the third-commonest 
long-term illness group after 
cardiovascular and mus-
culoskeletal diseases, with 
asthma being the second-
most common single condi-
tion reported after COPD.1
CAUSES
With asthma, the airways be-
come over-sensitive and react to 
stimuli that would normally not 
Eamonn Brady MPSI 
provides a clinical overview of 
the presentation, diagnosis and 
treatment options for asthma
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cause a problem, such as cold 
air or dust. Muscles around the 
wall of the airway tighten-up, 
making it narrow and difficult 
for air to flow in and out. The 
lining of the airways swells, and 
sticky mucus is produced. This 
makes it difficult for air to move 
in and out. Tightening of muscle 
around the airways can happen 
quickly and is the most common 
cause of mild asthma. The tight-
ening of muscle can be relieved 
with a reliever inhaler. However, 
the swelling and build-up of 
mucus happen more slowly and 
need a different treatment. This 
takes longer to clear up and is 
a serious problem in moderate-
to-severe asthma.
FACTS ABOUT ASTHMA
The exact cause of asthma 
is not known. According 
to the Asthma Insights and 
Realities in Ireland (AIRI) re-
port in 2002, 470,000 people 
have asthma in Ireland, 
meaning approxi-
mately one-in-eight 
of the population suffer 
from it. Ireland has 
the fourth-highest 
prevalence of asth-
ma in the world 
after Austral-
ia, New Zea-
land and the 
UK. The Irish 
P h a r m a c e u t i -
cal Health Care 
Association (IPHA) 
reported there 
were 600,000 GP 
consultations for 
asthma in 1997 
and it is likely this 
figure has risen 
since.1
There is a strong 
genetic link. If a par-
ent has asthma, the 
risk of their child get-
ting it doubles. If both 
parents have it, it doubles again. 
And if one in a family has asth-
ma, the risk of the other children 
getting it increases, but it is not 
known by how much. In adults, it 
is more common in women than 
men. Asthma can start at any 
age, but most commonly starts in 
childhood. Adult-onset asthma 
may develop after a respiratory 
tract infection. In many cases, 
asthma disappears during teen-
age years. Many asthma suffer-
ers also suffer from other allergic 
conditions such as hayfever, ec-
zema and hives. Asthmatics who 
also have hayfever find that their 
symptoms get worse during hay-
fever symptoms. In fact, research 
by Allergy UK found that 69 per 
cent of asthmatics who also had 
hayfever found their symptoms 
worsened during hayfever sea-
son. Asthma has got more com-
mon in recent years. The inci-
dence of asthma among 13- and 
14-year-olds has increased by 40 
per cent from 1995 to 2003.14 The 
exact reason for this is not known. 
Many aspects of modern living, 
such as changes in housing, diet 
and a more sterile home envi-
ronment may have contributed 
to the rise in asthma over recent 
decades. This theory is called the 
‘hygiene hypothesis’.
HYGIENE HYPOTHESIS
The ‘hygiene hypothesis’ is a the-
ory that lack of exposure in early 
childhood to infectious agents 
means that the child’s immune 
system has not been activated 
sufficiently during childhood. 
This lack of exposure is down to 
our super-clean world of mod-
ern living, including antibacteri-
al washes, vaccinations and gen-
eral sterility where children are 
not exposed to germs in a similar 
manner to previous generations 
of children. The theory hypoth-
eses that because the immune 
system is ‘not activated’ during 
Asthma in children is more 
common in boys than girls. 
Children who develop 
asthma at a very young age 
are more likely to ‘grow out’ 
of the condition as they get 
older. If asthma is moderate-
to-severe during childhood, 
it is more likely to continue 
into adulthood. During the 
teenage years, the symptoms 
of asthma disappear in 
about three-quarters of all 
children with the condition. 
Known risk factors for the 
development of asthma 
in children include:
A family history of asthma, 
or other related allergic 
conditions (known as 
atopic conditions) such 








particularly if the 
child’s mother smoked 
during pregnancy. 
Being born prematurely.
Being born with a 
low birth weight.
A child with asthma should 
be taught to recognise 
the initial symptoms of an 
asthma attack, how they 
should respond, and when 
they should seek medical 
attention. Some children are 
less likely to develop asthma 
than others. Studies have 
found those children who 
are given fewer antibiotics 
and those who live on or 
near farms have less asthma 
than children with different 
backgrounds. Medical 
researchers explain this with 
the ‘hygiene hypothesis’. 
childhood, this leads to the immune 
system becoming over-sensitive to 
common substances such as pollen, 
dust-mites and animal fur, leading 
to the higher incidence of auto-im-
mune conditions like asthma, hayfe-
ver and eczema in recent years. One 
of the first scientific explanations of 
this theory was by a lecturer in epi-
demiology from the London School 
of Hygiene and Tropical Medicine, 
David P Strachan, who published 
a paper on the theory in the British 
Medical Journal in 1989.15 He noticed 
that children from larger families 
were less likely to suffer from au-
toimmune conditions like asthma. 
Families have got smaller in the 
Western world over the last 40 years, 
meaning less exposure to germs 
and infections; it is over the same 
period that health authorities have 
seen an explosion in autoimmune 
conditions such as asthma. Further 
studies have been conducted since, 
supporting the theory. For example, 
studies show that autoimmune dis-
eases are less common in develop-
ing countries, however when im-
migrants from developing countries 
come to live in developed countries 
where living environments are more 
sterile, these immigrants suffer from 
increased levels of autoimmune 
conditions like asthma and the rate 
of autoimmune conditions increases 
the longer immigrants live in devel-
oped countries.16 It is a difficult is-
sue to tackle for healthcare profes-
sionals advising parents who want 
the best for their children; common 
sense tells us all that cleanliness is 
important. As a pharmacist, it is dif-
ficult to advise on the best balance 
for parents in relation to this theory. 
No journal or book will give a phar-
macist exact advice. In my opinion, 
a balanced view is to ensure children 
are administered important vaccines 
but ‘allow kids be kids’, let children 
play outside with friends and try not 
to worry about them coming in con-
tact with dirt and germs, but always 
be cautious with children with life 
ASTHMA IN CHILDREN
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threatening food allergies.
These symptoms may occur in episodes, 
perhaps brought on by colds or chest infec-
tions, exercise, change of temperature, dust 
or other irritants in the air, or by an allergy, 
ie, pollen or animals. Episodes at night are 
common, often affecting sleep.
Common triggers
Anything that irritates the airways and 
brings on the symptoms of asthma is called 
a trigger. Common triggers include house 
dust mites, animal fur, pollen, tobacco 
smoke, exercise, cold air and chest infec-
tions. Other triggers which are less common 
include non-steroidal anti-inflammatory 
drugs such as ibuprofen and diclofenac, 
emotional factors such as stress, sulphites 
in some foods and drinks (found in certain 
wines and used as a preservative in some 
foods such as fruit juices and jam), mould 
or damp in houses, and food allergies, ie, 
nut allergy. 
What happens during an asthma attack? 
During an asthma attack, something trig-
gers inflammation, a natural biological pro-
cess. Inflammation is one of the ways that 
the body’s immune system fights infection. 
If the body detects a lung infection, it starts 
the process of inflammation. White blood 
cells engulf the infection area to kill the in-
fection and prevent it spreading. The white 
blood cells cause the airways to swell and 
produce mucus. In an asthmatic, the air-
ways are over-sensitive to the effects of in-
flammation. As a result, too much mucus is 
produced and the airways swell more than 
usual. Also, as a response to the inflamma-
tion, the muscles surrounding the airways 
begin to contract, making the airways nar-
rower and narrower. The combination of 
excess mucus, swelling and contraction of 
the airways makes breathing difficult and 
produces the wheezing and coughing that 
is associated with asthma.
Non-pharmacological management
Asthmatics should be advised strongly 
not to smoke and to lose weight.2 Allergen 
avoidance measures may be helpful, but 
the benefit of avoiding allergens such as 
dust mites and animal fur has not been 
proven in studies.3, 4 Currently, there is in-
sufficient or no evidence of the clinical ben-
efit of complementary therapy for asthma, 
such as Chinese medicine, acupuncture, 
breathing exercises and homeopathy.5 
TREATMENT
There is no cure for asthma. Symptoms can 
come and go throughout the person’s life. 
Treatment can help control the condition. 
Treatment is based on relief of symptoms 
and preventing future symptoms and at-
tacks from developing. Successful preven-
tion can be achieved through a combina-
tion of medicines, lifestyle changes and 
identification and avoiding asthma triggers. 
Reliever inhalers
A short-acting beta 2-agonist opens the air-
ways. These work quickly to relieve asthma. 
They work by relaxing the muscles sur-
rounding the narrowed airways. Examples 
of beta 2-agonists include salbutamol and 
terbutaline. They are usually blue in colour. 
They are generally safe medicines with few 
side-effects, unless they are over-used. It 
is important for every asthmatic to have a 
beta-2 agonist inhaler. If an asthmatic needs 
to use their beta agonist inhaler too regularly 
(three or more times per week), they should 
have their therapy reviewed. The main side-
effects include a mild shaking of the hands, 
headache and muscle cramps. These usually 
only occur with high doses of relievers and 
usually only last for a few minutes. Excessive 
use of short-acting relievers has been asso-
ciated with asthma deaths.5, 6 This is not the 
fault of the reliever medication, but down to 
the fact that the patient failed to get treat-
ment for their worsening asthma symptoms. 
In exercise-induced asthma, suffers are ad-
vised to use a short acting beta 2-agonist 
10-to-15 minutes before they exercise, and 
again after two hours of prolonged exercise, 
or when they finish.
Preventer inhalers
Preventer inhalers are slower-acting inhal-
ers that reduce inflammation in the airways 
and prevent asthma attacks occurring. The 
preventer inhaler must be used daily for 
some time before full benefit is achieved. 
The preventer inhaler usually contains an 
inhaled corticosteroid. Examples of pre-
venter medicines include beclomethasone, 
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The incidence of epistaxis during long term treatment was higher than 10% but was generally mild to 
moderate in intensity1
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DIAGNOSIS OF ASTHMAhalers  are often brown, red or 
orange. The dose of inhaler will 
be increased gradually until 
symptoms ease. For example, 
a patient may start on a be-
clomethasone 100mcg inhaler 
and may be put on a beclometh-
asone 250mcg inhaler if there 
is not enough improvement in 
symptoms. Preventer treatment 
is normally recommended if the 
patient:
•	 Has asthma symptoms more 
than twice a week. 
•	 Wakes up once a week due to 
asthma symptoms. 
•	 Must use a reliever inhaler 
more than twice a week.
Regular inhaled corticosteroids 
have been shown to reduce 
symptoms, exacerbations, hos-
pital readmissions and asthma 
deaths.5,7,8-11 The majority of pa-
tients require a dose of less than 
400mcg per day to achieve maxi-
mum or near-maximum benefit. 
Side-effects are minimal at this 
dose. Smoking can reduce the 
effects of preventer inhalers. 
Preventers are very safe at usual 
doses, although they can cause 
some side-effects at high doses, 
especially over long-term use. 
The main side-effect of preven-
ter inhalers is a fungal infection 
(oral candidiasis) of the mouth 
or throat. 
This can be prevented by rins-
ing the mouth with water after 
inhaling a dose. The patient may 
also develop a hoarse voice. Us-
ing a spacer can help prevent 
these side-effects.
Long-acting reliever inhaler
If short-acting bets 2-agonist 
inhalers and preventer inhalers 
are not providing enough symp-
tom relief, a long-acting reliever 
(long-acting beta 2-agonist) may 
be tried. Inhalers combining an 
inhaled steroid and a long-act-
ing bronchodilator (combina-
tion inhaler) are more common-
ly prescribed than long-acting 
beta 2-agonists on their own. 
Long-acting beta 2-agonists 
work in the same way as short-
acting relievers, but they take 
longer to work and can last up 
to 12 hours. A salmeterol inhaler 
is an example of a long-acting 
reliever inhaler used in Ireland. 
Long-acting relievers may cause 
similar side-effects to short-act-
ing relievers, including a mild 
shaking of the hands, headache 
and muscle cramps. Long-acting 
reliever inhalers should only 
be used in combination with a 
preventer inhaler. Studies have 
shown that using a long-acting 
reliever on its own (without a 
combination corticosteroid) can 
increase asthma attacks and can 
even increase the risk of death 
from asthma, though increased 
risk of death is small.17 In No-
vember 2005, the Food and Drug 
Administration in the United 
States issued an alert indicat-
ing the potential increase risk of 
worsening symptoms and some-
times death associated with the 
use of long-acting beta 2-ago-
nists on their own.18 
Combination inhalers
Examples of combination inhal-
ers containing long-acting beta 
2-agonists and steroids include 
Seretide and Symbicort. Combi-
nation inhalers containing beta 
2-agonists and corticosteroids 
can be very effective in attain-
ing asthma control. They have 
been shown to have better out-
comes compared to leukotriene 
receptor antagonists such as 
montelukast.19 Both treatment 
options lead to improved asth-
ma control; however, compared 
to leukotriene receptor antago-
nists, the addition of a long-
acting beta 2-agonist to inhaled 
corticosteroids is associated 
with significantly improved lung 
The following questions 
can help ascertain if 
asthma is the problem
Is there a family 
history of asthma? 
Are symptoms frequent and 
do they affect quality of life? 
Has there been an 
attack or recurrent 
attacks of wheezing? 
Is there a regular 
night-time cough?
Does exercise trigger 
wheezing or coughing? 
Is there wheezing, chest 
tightness, or cough after 
exposure to airborne 
allergens or pollutants? 
Does the patient suffer from 
constant chest infections? 
Do chest infections take 
a long time to clear up?
Are symptoms improved 
by when using a 
reliever inhaler? 
❋ ❋ ❋
The following tests are 
often done to confirm the 
diagnosis of asthma
1
Spirometry is a simple 
breathing test that gives 
measurements of lung 
function. A spirometer is 
the device that is used to 
make the measurements. It 
is common to measure lung 
function with a spirometer 
before and after a dose 
of reliever to see if lung 
function has improved.
2
Peak expiratory flow rate 
(PEFR) is a breathing test. 
It uses a simple hand-held 
device called a peak flow 
meter, which a patient 
blows into to measure lung 
function. The PEFR test is 
only suitable for children 
over five years of age.
3
An exercise test to check 
if exercise worsens 
asthma symptoms.
function, symptom-free days, need 
for short-term beta 2-agonists, night 
awakenings, and quality of life.19 
However, the magnitude of some of 
these differences is small.19
Other preventer medications
If treatment of asthma is still not suc-
cessful, additional preventer medi-
cines can be tried. Two possible al-
ternatives include:
•	 Leukotriene receptor antagonists 
(montelukast): Act by blocking part 
of the chemical reaction involved in 
inflammation of the airways. 
•	 Theophyllines: Helps widen the 
airways by relaxing the muscles 
around them.
If asthma is still not under control, 
regular oral corticosteroids may be 
prescribed. This treatment is usually 
monitored by a respiratory specialist. 
Long-term use of oral corticosteroids 
has possible serious side-effects, so 
they are only used once other treat-
ment options have been tried. Theo-
phylline is known to cause potential 
side-effects, including headaches, 
nausea, insomnia, vomiting, irrita-
bility and stomach upsets. These can 
usually be avoided by adjusting the 
dose. Leukotriene receptor agonists 
do not usually cause side-effects, 
although there have been reports of 
stomach upsets, feeling thirsty and 
headache.
Occasional use of oral corticoster-
oids
Most patients only need to take a 
course of oral corticosteroids for 
one or two weeks. Once the asthma 
symptoms are under control, the 
dose can be reduced slowly over a 
few days. Oral corticosteroids can 
cause side-effects if they are taken 
for more than three months or if they 
are taken frequently (three or four 
courses of corticosteroids a year). 
Side-effects can include: 
•	 Weight gain.
•	 Thinning of the skin.     
•	 Osteoporosis. 
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•	 Hypertension.
•	 Diabetes. 
•	 Cataracts and glaucoma.    
•	 Easy bruising.   
•	 Muscle weakness.
To minimise the risk of taking oral corticos-
teroids:
•	 Eat a healthy, balanced diet with plenty 
of calcium.  
•	 Maintain a healthy body weight.  
•	 Stop smoking.   
•	 Only drink alcohol in moderation. 
•	 Do regular exercise.
When can therapy be reduced? 
Once control is achieved and sustained, 
gradual stepping-down of therapy is recom-
mended.5 Good control is reflected by the ab-
sence of night-time symptoms, no symptoms 
on exercise and the use of relievers less than 
three times a week. Patients should be main-
tained on the lowest effective dose of inhaled 
steroids, with reductions of 25-50% being 
considered every three months.
Spacer devices 
Spacers are large plastic or metal contain-
ers with a mouthpiece at one end and a hole 
for the inhaler at the other. The medicine is 
puffed into the spacer by the inhaler and it is 
then breathed in through the spacer mouth-
piece. Spacer devices in combination with 
metered dose inhalers (MDI) have a num-
ber of advantages: a) no need to co-ordinate 
inhaler activation with inspiration, b) im-
provement in lung deposition and c) reduc-
tion in oropharyngeal deposition (resulting 
in fewer local side effects and lower systemic 
absorption).2 Some inhalers emit an aero-
sol jet when pressed. These work better if 
given through a spacer, which increases the 
amount of medication that reaches the lungs 
and reduce side effects.6 Some patients, es-
pecially children and elderly patients, find 
using inhalers difficult, and spacers can 
help. However, spacers are often advised 
even for patients who use inhalers well as 
they improve the distribution of medication 
in the lungs. Spacers are also good for reduc-
ing the risk of thrush in the mouth or throat 
with corticosteroid inhalers. When a spacer 
device is being used, only one puff of the in-
haler must occur at a time.
ASTHMA DEATHS
Underestimating the severity of the fatal 
attack by the doctor, patient or relatives is 
considered to be the biggest cause of death 
in asthmatics.5,12,13 There were 92 asthma-
related deaths in Ireland in 1999.1 The risk 
of dying from asthma increases with age and 
asthma-related deaths are extremely rare in 
children. Patients at most at risk of death are 
those who have severe asthma, are obese, 
have a history of non-compliance with ther-
apy and have one or more adverse psycho-
logical factors, such as: Alcohol or drug use, 
employment or income problems, social iso-
lation, or current or recent tranquilliser use. 
ASTHMA AND PREGNANCY
Medication used for asthma will not cause 
any problems for the developing baby in the 
womb. Due to the changes that take place in 
the body during pregnancy, asthma symp-
toms may change during pregnancy. For 
some women, asthma improves; for others 
asthma worsens and for others, asthma stays 
the same. The most severe asthma symp-
toms experienced by pregnant women tend 
to occur between the 24th and 36th week of 
pregnancy. Symptoms then decrease signifi-
cantly during the last month of pregnancy. 
Only 10 per cent of women experience 
asthma symptoms during labour and deliv-
ery, and these symptoms can normally be 
controlled using reliever medicine.
Asthmatics who are pregnant should man-
age their asthma in the same way as before 
pregnancy. The medicines used for asthma 
have been proven to be safe to take during 
pregnancy and when breastfeeding. The one 
exception is leukotriene receptor antago-
nists (Montelukast). There is no evidence 
that it can harm babies during pregnancy 
and breastfeeding. However, there is not 
enough evidence about its safety compared 
with other asthma medications.
However, if leukotriene receptor antago-
nists are needed to control asthma during 
pregnancy, the GP or asthma clinic may rec-
ommend that they are continued. This is be-
cause the risks to the patient and child from 
uncontrolled asthma are far higher than any 
potential risk from this medicine. Theophyl-
line is often avoided during pregnancy and 
breastfeeding because of reports of neonatal 
irritability and apnoea. ●
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P
erhaps unsurprisingly, the 
best place to start a discus-
sion on the benefits of early 
diagnosis and treatment 
in chronic obstructive pul-
monary disease (COPD) 
is with the definition of COPD from the 
Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines. The 
GOLD guidelines talk about COPD being 
a common, preventable, treatable lung 
condition characterised by airflow limi-
tation that is not fully reversible and is 
usually caused by significant exposure 
to noxious gases (ie, cigarette smoke). 
GOLD reminds us that COPD is also 
normally progressive.
Let’s look at that. How common is 
COPD in Ireland? 
The incidence of COPD in Ireland 
is 10 per cent of the adult popula-
tion. Every COPD talk I’ve ever 
attended has used the iceberg 
analogy. That is to say that the 
visible iceberg above the water rep-
resents the 110,000 Irish patients we 
The early diagnosis of COPD has a 
significant potential to benefit patients 
and reduce costs to the health service
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have diagnosed with COPD and the larger 
iceberg under the water reminds us that 
there are 200,000 patients living with COPD 
who have not yet been diagnosed. 
In fact, I believe there are two icebergs in 
COPD, the second one representing those 
110,000 patients we have diagnosed with 
COPD. If you visualise the COPD patients in 
your practice, you will probably be visu-
alising the symptomatic and exacerbating 
patients. Yet only 15 per cent of your COPD 
patients fit into this bracket. So, the second 
iceberg in COPD is within those patients 
already diagnosed with COPD. Above the 
water are the exacerbating patients but re-
member that underneath the water are over 
half the patients with COPD in your practice 
who will have at most one exacerbation in a 
year and who we may be less aware of.
Next, GOLD says COPD is preventable. 
For the majority of our Irish patients, smok-
ing will be the only cause of their COPD. 
That we are reminded that COPD is prevent-
able is a call to arms for general practitio-
ners (GPs) with regards to smoking cessa-
tion. Smoking cessation has been shown to 
be the most significant intervention to slow 
the rate of decline of lung function and the 
earlier a smoker stops smoking, the more 
lung function is preserved. Pharmacother-
apy and nicotine replacement are known 
to reliably increase long-term smoking ab-
stinence rates. The effectiveness and safety 
of e-cigarettes as a smoking cessation aid is 
uncertain at present.
So why are there 200,000 patients living 
with COPD in Ireland who are undiag-
nosed? There are patient factors, GP or 
practice factors, and system factors.
Patient factors: COPD progresses re-
lentlessly, but slowly, and as such, many 
patients do not realise that they have a 
problem. COPD patients may associate 
their symptoms (ie, dyspnoea) with the 
ageing process, with being less active, with 
being deconditioned and less ‘fit’. They may 
normalise their cough as a ‘smoker’s cough’ 
and do not consider it to be a sign of illness. 
COPD patients can be stoic regarding their 
condition, known as the ‘silence of COPD’.
GP and practice factors: In the course of 
a busy winter flu season, patients pre-
senting with recurrent chest infections 
may not be regarded as at-risk of having 
COPD. Also, as COPD patients tend to 
underemphasise their symptoms, we may 
tend towards being less aggressive when 
it comes to investigating their symptoms.  
Patients with COPD commonly have co-
morbidities and these conditions may be 
perceived to be more pressing and perhaps 
easier to diagnose and manage. There is 
concern among some doctors regarding the 
accuracy of spirometry performed in gen-
eral practice. However, studies show that 
accurate spirometry can be performed in 
general practice, where the practice nurses 
have appropriate training and interest.
System factors: Irish general practice 
is contracted to a 40-year-old general 
medical services (GMS) contract, which 
is predicated on the treatment of acute 
illness. Reflecting on the changes which 
have taken place in your television since 
1978, and considering that similar changes 
have taken place in medicine with regards 
to the diagnosis and treatment of patients 
during this time, gives an idea of how 
disadvantaged Irish patients and Irish GPs 
have been when it comes to diagnosing 
and managing chronic illnesses. Moreover, 
COPD requires spirometry to confirm the 
diagnosis and there is no HSE funding 
to general practice to support diagnostic 
spirometry. Until 2019, there has been no 
funding towards a ‘COPD cycle of care’, 
which might ensure that Irish COPD pa-
tients received evidence-based care.  
However, the recent introduction of 
funding to Irish GPs to support case find-
ing and a COPD cycle of care in chronic 
disease management should help identify 
more of those 200,000 Irish people living 
with undiagnosed COPD. It should also 
improve the quality of care COPD patients 
receive.
GOLD also reminds us that COPD is 
treatable. Pharmacological therapy can 
reduce COPD symptoms, reduce the 
frequency and severity of exacerbations, 
and improve health status and exercise 
tolerance. GOLD states that each phar-
macologic treatment regimen should be 
individualised and guided by the severity 
of symptoms, risk of exacerbations, side-
effects, comorbidities, drug availability and 
cost, and the patient’s response, preference 
and ability to use various drug delivery 
devices.
Finally, GOLD states that COPD is a pro-
gressive condition. Degenerative changes 
in lung function with age in non-smoking 
healthy adults result in the loss of 25 per 
cent of lung function (as defined by a 
decrease in FEV1) by the age of 75. Smok-
ing is known to accelerate this loss of lung 
function considerably, as demonstrated 
by the Fletcher-Peto graph. Additionally, 
every purulent COPD exacerbation further 
decreases a patient’s quality of life, longev-
ity and reduces lung function.
So why should we worry about our 
200,000 Irish patients who are living with 
COPD and have yet to be diagnosed? Why 
is early diagnosis of COPD going to help?
Diagnosis of COPD usually does not 
occur until significant lung function has 
already been lost. By the time patients 
recognise that they have symptoms, their 
airflow limitation, as defined by a reduction 
in FEV1, has usually fallen to about 50 per 
cent of predicted. They will be having two 
or more exacerbations per year and there is 
a significant amount of systemic inflamma-
tion leading to comorbidities.
Direct costs of respiratory disease ac-
count for 6 per cent of the total healthcare 
budget in the EU, with COPD account-
ing for 56 per cent (€38.6 billion) of this 
cost. COPD exacerbations account for the 
greatest proportion of the total economic 
burden associated with COPD. So, the 
financial costs of COPD are high. As well as 
the direct costs of hospitalisation and other 
healthcare costs, there are other indirect 
costs of disability, lost productivity, carer 
support and family costs. As Ireland has 
the highest rate of COPD hospitalisations 
among the Organisation for Economic Co-
operation and Development (OECD) coun-
tries (395 COPD admissions per 100,000 
population), we can be sure that COPD is 
contributing significantly to both health-
care costs and our significant trolley crisis.
It is evident that if we can diagnose 
COPD earlier in the course of the illness, 
we can improve patient outcomes by 
focusing on smoking cessation, increas-
ing uptake of influenza and pneumonia 
vaccinations, ensuring adequate nutrition, 
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increasing physical activity among our 
patients, and ensuring patients are on ev-
idence-based inhaled pharmacotherapy, 
which is appropriate for each individual 
patient and which is shown to decrease 
exacerbation rates.
Smoking cessation has the greatest 
capacity to influence the natural history 
of COPD. If effective resources and time 
are dedicated to smoking cessation, long-
term quit success rates of up to 25 per 
cent can be achieved. Smoking cessation 
interventions are more successful in those 
who are actually given a firm diagnosis. 
Influenza vaccination can reduce seri-
ous illness (such as lower respiratory 
tract infections requiring hospitalisation) 
and death in COPD patients. Pneumo-
coccal vaccinations have been shown to 
reduce community-acquired pneumonia 
in patients under 65 with severe airflow 
limitation (FEV1<40 per cent).
Early diagnosis allows for earlier lifestyle 
changes, such as exercise and pulmo-
nary rehabilitation. As already discussed, 
exertional dyspnoea often leads patients 
to reduce their exercise and activities of 
daily living to reduce the intensity of their 
distress. This reduction in activities of daily 
living leads to deconditioning which, in 
turn, can lead to increased dyspnoea.
Early pharmacological intervention 
can improve the health and exercise 
capacity of COPD patients and reduce 
COPD exacerbations, even in patients 
with mild-to-moderate COPD. The 2017 
GOLD guidelines have made the treat-
ment decision-making pathways in COPD 
more doctor-friendly, as they uncoupled 
spirometry findings from treatment 
algorithms. As spirometry is not specifi-
cally funded in the new chronic disease 
management pathways in the Irish GP 
GMS, this development is particularly 
GP-friendly. Patients require spirometry 
to confirm the diagnosis. 
However, once confirmed, the decision 
relating to choice of inhaled pharmaco-
therapy is based on four questions:
1. Does the patient have asthma  
and COPD? 
If yes, a long-acting β-agonist/inhaled cor-
ticosteroid (LABA/ICS) combination is the 
first choice in COPD patients with a history 
of asthma.
2. How many exacerbations has the pa-
tient had in the last year? 
3. Has the patient got symptoms?
Zero or one exacerbations and no symptoms, 
the patient should start with a short-acting 
β-agonist, increasing to single-agent long-
acting bronchodilator (ie, a long-acting 
muscarinic antagonist (LAMA) or LABA).
Zero or one exacerbations and symptom-
atic, the patient should start with a single-
agent long-acting bronchodilator (ie, a 
LAMA or LABA), increasing to a dual-acting 
bronchodilator (ie, LAMA/LABA combina-
tion). 
Two or more exacerbations or one hos-
pitalisation and no symptoms, the patient 
should start with a LAMA, increasing to a 
LAMA/LABA and then a LAMA/LABA/ICS 
triple therapy combination if the patient 
continues to have exacerbations.
Two or more exacerbations or one hos-
pitalisation and symptomatic, the patient 
should start with a LAMA, increasing to a 
LAMA/LABA and then LAMA/LABA/ICS if 
the patient continues to have exacerbations.
4. What is the patient’s eosinophil count?
Blood eosinophil counts have been shown 
to predict steroid responsiveness in 
reducing exacerbations in COPD and the 
2019 GOLD guidelines have introduced 
blood eosinophil counts to the treatment 
algorithms. 
If the blood eosinophil counts ≥300 
cells/µL, a LABA/ICS combination has the 
greatest likelihood of reducing exacerba-
tions. Even in patients without a previous 
history of frequent exacerbations (ie, they 
have had one exacerbation in the last 
year), an ICS has been shown to decrease 
the risk of future exacerbations.
In patients with frequent exacerbations 
and blood eosinophil counts ≥100 cells/
µL, an ICS should be considered earlier 
in the course of treatment. This refers to 
patients who are diagnosed with COPD, 
are symptomatic and have had two or 
more exacerbations in the last year. During 
follow-up with these patients, you should 
consider the early introduction of an ICS 
in addition to a single- or dual-acting 
bronchodilator.
So how can we promote earlier diagnosis 
of our patients with COPD? 
There are a number of strategies which can 
be used to facilitate the earlier diagnosis of 
COPD. 
For the first time in Irish general prac-
tice, we have funding to support screening 
at-risk patients, case finding and chronic 
disease management. It is unfortunate that 
there is not dedicated funding to also facili-
tate spirometry, which is essential for the 
diagnosis of COPD. 
However, I believe the funding for chronic 
disease management, including COPD, will 
help identify more of those 200,000 Irish 
people living with undiagnosed COPD. It 
should also improve the quality-of-care 
COPD patients receive.
We should consider COPD in any patient 
who is a current smoker or ex-smoker 
over the age of 35 who has any respiratory 
symptoms, particularly cough, sputum, dys-
pnoea, wheeze or recurrent chest infections. 
Opportunistic spirometry to detect COPD 
in these patients has been shown to be 
cost-effective and forms part of the National 
Institute for Health and Care Excellence 
(NICE) guidelines in the UK. If spirom-
etry is not available in your practice or not 
financially viable, consider referral of these 
patients to a respiratory clinic for diagnostic 
spirometry.
In summary, early diagnosis of COPD 
has the potential to benefit patients and 
save costs for the HSE. An early diagnosis 
will encourage smoking cessation, facilitate 
exercise interventions, facilitate earlier 
influenza and pneumonia vaccination and 
enable earlier inhaler treatment to pre-
vent exacerbations and hospitalisations. 
Considering that we have the worst rate of 
COPD exacerbations leading to hospitalisa-
tion in the OECD, surely our COPD patients 
deserve more. ●
This article has been written in associa-
tion with A.Menarini Pharmaceuticals. 
A.Menarini Pharmaceuticals had no input 
into the content of this piece. 
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As people get older, they are at greater risk for common eye dis-eases and conditions, including age-related macular degenera-
tion (AMD), cataracts, glaucoma and dry 
eyes. While cataracts are treated with sur-
gical intervention and glaucoma with pre-
scription medication, there are products 
available over-the-counter to treat dry eyes 
and potentially help with AMD.
DRY EYES
When a person does not produce enough 
quality tears to lubricate and nourish the 
eye, dry eye occurs. Tears are required to 
maintain the health of the eye, especially the 
anterior surface, and to provide clear vision.1 
The act of blinking spreads tears across the 
cornea, which provides lubrication, reduces 
the risk of eye infections and washes away 
foreign matter in the eye. This keeps the 
surface of the eyes smooth and clear. Excess 
tears flow into drainage ducts in the inner 
corners of the eyelids, which drain into the 
back of the nose. Dry eye is a common and 
often chronic problem, particularly in older 
adults and can occur when tear production 
and drainage are not in balance. 
When dry eye occurs, this is due either to 
not enough tears being produced, or else the 
tears are not good quality.
Lifting the lid 
on eye care
Donna Cosgrove PhD MPSI looks at the range of eye conditions that 
typically present in the pharmacy
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• Inadequate amount of tears: 
Tear production tends to reduce 
as we age and can be caused by 
various medical conditions, or as 
a side effect of certain medicines 
(see list of ‘Medications that may cause dry 
eyes’). Environmental conditions 
can also decrease tear volume by 
increasing the rate of tear evapo-
ration. When the normal amount 
of tear production decreases or 
tears evaporate too quickly from 
the eyes, symptoms of dry eye 
can develop.
• Poor quality of tears: Tears 
are made up of oil, water and 
mucus (Figure 1). Each of these 
layers protects and nourishes the 
eye. The smooth oil layer helps 
prevent evaporation of the water 
layer, while the mucin layer 
allows uniform distribution of 
the tears over the eye surface. If 
the tears evaporate too quickly 
or do not spread evenly over 
the cornea due to deficiencies 
with any of the three layers, dry 
eye symptoms can develop. The 
most common form of dry eyes 
is due to inadequate amount 
of the water layer of tears. This 
condition, called keratoconjunc-
tivitis sicca (KCS), is also referred 
to as dry ‘eye syndrome’.
Mild or moderate cases of dry eye 
can be treated with tear substitutes, 
designed to mimic the tears pro-
duced in the eye. The underlying 
mechanism of symptomatic im-
provement with tear supplementa-
tion is still poorly understood. It has 
been proposed that improvements 
are due to the increased tear volume, 
improved tear stabilisation, 
reduced tear osmolarity, a 
dilution of inflammatory 
biomarkers, or a combina-
tion of these.3 Hydrogel 
polymers, such as those con-
taining hypromellose (also called 
hydroxypropyl methylcellulose) or 
carbomer are effective for treating 
mild cases of dry eye. Hypromellose 
is frequently recommended as first-
line, but to achieve adequate relief 
of symptoms, use may be required 
up to hourly. In these cases, more 
viscous products may be required, ie, 
carbomer 980, which binds moisture 
to the ocular surface, increasing the 
time for which moisture is retained. 
Carboxymethylcellulose drops are 
often considered if the hydrogel 
polymer products do not provide 
enough relief. In more severe cases 
or if symptoms are chronic, it may be 
necessary to use a lubricant with vis-
cosity-increasing properties, such as 
Figure 1: Tear film composition1
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sodium hyaluronate. Hydroxypropyl 
guar products increase in viscosity 
on contact with the ocular surface, 
forming a bio-adhesive gel. This 
mimics the mucous layer 
of the tear film, increasing 
aqueous retention. These 
products may be benefi-
cial in mucous and aqueous 
deficiency. Preservative-free eye 
drops are available for people who 
wear soft contact lenses, and for 
those whose eyes are irritated by eye 
drops containing a preservative. Eye 
ointment is also available — research 
suggests a superior long-lasting ef-
fect compared with aqueous based 
ocular lubricants.
Lifestyle changes can improve 
the symptoms of dry eyes, such as 
use of humidifiers, stopping smok-
ing, taking regular breaks from the 
computer to encourage blinking, and 
increasing dietary omega-3 fatty acid 
intake.
Age-related macular degeneration
AMD is the term given to ageing 
changes without any other 
obvious cause that occur in 
the central area of the retina 
(macula). AMD is painless 
but leads to the gradual impair-
ment of vision.4 It can sometimes 
cause a rapid reduction in vision. It 
predominantly affects the central 
vision, which is used for reading 
and recognising faces. AMD is more 
common with older age, family his-
tory of AMD, smoking, hypertension, 
BMI of 30kg/m2 or higher, diet low in 
omega 3 and 6, vitamins, carotenoid 
and minerals, a diet high in fat, and 
lack of exercise.
There are two forms of AMD:5
• Dry AMD: This causes central 
vision to become dimmer, and 
as the disease progresses, dis-
torted. This is the most common 
form of AMD (90 per cent). The 
cells of the macula at the back of 
the eye become thinner and less 
efficient as we age. These cells 
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lose lutein, a pigment essential to good 
eyesight. AMD is an acceleration of the 
natural ageing process at the back of 
the eye. Dry AMD cannot be treated, 
but taking lutein supplements, follow-
ing a healthy diet and lifestyle with 
plenty of exercise and using good UV 
protective sunglasses can stabilise the 
progression of the condition.
• Wet (neovascular) AMD: Abnormal 
blood vessels (in the choriocapillaris) 
behind the retina start to leak, which 
causes a drop in oxygen supply to the 
cells in the macula. The body responds 
by generating more abnormal (frag-
ile) blood vessels and scar tissue. This 
process causes permanent vision loss 
to the central visual field. Unlike dry 
AMD, wet AMD causes rapid vision 
loss and requires treatment. Wet AMD 
in particular is thought to have strong 
genetic link, so if a family member has 
had wet AMD, it is a good idea to take a 
lutein supplement, follow a healthy diet 
and get plenty of exercise. Wet AMD 
does not develop suddenly; dry AMD 
usually occurs first, although the indi-
vidual may not have been aware of it.
Wet AMD is treated by a specialist ophthal-
mologist using either photodynamic ther-
apy, laser photocoagulation, or injections 
which prevent the formation of scar tissue 
and promote better healing at the macula. 
Anti-VEGF injections (ie, aflibercept, beva-
cizumab, ranibizumab) are given directly 
into the eyes. This prevents worsening of 
vision in 90 per cent of cases and improves 
vision in 30 per cent.6  These drugs bind 
to circulating vascular endothelial growth 
factors (VEGF) and inhibit their activity. 
This decreases the proliferation of the fragile 
blood vessels in the choriocapillaris.
Vitamins A, C and E are thought to main-
tain healthy cells and tissues in the eye. 
More recently, interest has grown in another 
antioxidant, lutein, and a similar substance, 
zeaxanthin. Both are yellow plant pigments 
(ie, the yellow and orange in peppers, 
sweetcorn and saffron). Green leafy vegeta-
bles such as kale, spinach and broccoli also 
have high levels of lutein.7  Macular pigment 
is made up of three carotenoids: Lutein, 
zeaxanthin and meso-zeaxanthin. Meso-
zeaxanthin is not typically found in diet, but 
has been identified in some fish species. It 
is thought to be formed at the macula by 
conversion from lutein, but the mechanism 
for this has not been confirmed.8 Anti-
oxidants present in the retina (vitamin C, 
vitamin E, carotenoids, selenium and zinc) 
may prevent cellular damage by reacting 
with free radicals produced in the process 
of absorbing light.9 Dietary supplements 
are available, with varying combinations of 
these antioxidants and carotenoids. Mul-
tiple research studies have been performed 
to examine the effect of supplementation on 
macular degeneration. The Age-Related Eye 
Disease Study (AREDS) investigated the use 
of vitamin C 500mg, vitamin E 400 IU, beta 
carotene 15mg and zinc 80mg in the pro-
gression of macular degeneration. Results 
were positive in some groups, with patients 
experiencing a modest delay of 20-to-25 per 
cent in progression to advanced AMD at 
seven-year follow-up.4 
A separate study published in 20168 that 
included 49 patients evaluated the effect of 
once-daily oral macular pigment supple-
mentation in eyes with retinal pathology 
after six months. Supplementation con-
sisted of 10mg lutein, 2mg zeaxanthin, 
and 10mg meso-zeaxanthin (Macushield). 
Results showed an increase in the mean 
macular pigment density, and significant 
improvement in glare disability and low-
contrast sensitivity (the ability to distinguish 
an object from its background). The authors 
suggest that these findings warrant further 
investigation in larger studies with a longer 
follow-up period. The effects and benefits of 
each individual component in the supple-
ments on AMD progression is unclear, as 
a combined supplement was used.4 The 
Meso-zeaxanthin Ocular Supplementation 
Trial (MOST) AMD study10 was conducted 
to examine the effect of sustained supple-
mentation with carotenoids on visual func-
tion and disease progression. Forty-seven 
individuals completed the study to the 
36-month follow-up point. Findings indi-
cate that the inclusion of meso-zeaxanthin 
in a supplement formulation confer benefits 
in terms of macular pigment increase, and 
in terms of enhanced contrast sensitivity in 
subjects with early AMD. Although macular 
pigment increased after supplementation 
of all the carotenoids examined (lutein, 
zeaxanthin and meso-zeaxanthin), the 
inclusion of meso-zeaxanthin may lead to 
the best results. Researchers also observed 
benefits with sustained supplementation 
with the macular carotenoids over a three-
year period in patients with early AMD. 
Although many studies indicate positive 
results, for now, neither the NHS or HSE 
recommend prescription of these products, 
and a Cochrane review recommends that 
further trials are needed to promote the use 
of antioxidants and their role in the progres-
sion of AMD.9 ●
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Vitamins A, C and E are 
thought to maintain healthy 
cells and tissues in the eye...
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Channel your inner Steve 
McQueen with the Mustang 
Bullitt, writes Morgan 
Flanagan Creagh
I
n 1968, Lieutenant Frank Bullitt, 
played by Steve McQueen, famously 
hurtled through the mean streets of 
San Francisco, hot on the heels of a 
dastardly, black Dodge Charger in 
the blockbuster film Bullitt. After the movie, 
the Mustang GT Fastback reached superstar-
dom and Ford is now celebrating its 50th an-
niversary with a special, souped-up Mustang 
GT Bullitt. 
The supremely cool Mustang is painted in 
the same Dark Highland Green as the movie 
car and they have completely de-badged the 
exterior, except for one logo at the back that 
simply says ‘Bullitt’. It was mentioned to me 
that it looked like a prop car from the Fast & 
Furious franchise, and I’d have to agree; for a 
stock car, it has an undeniably custom look. 
It has also been bestowed with a behemoth 
5.0-litre, V8 engine that makes more noise 
than Croke Park on match day.
Mustangs have a reputation for being 
‘widow-makers’, especially the quick ones, 
and I learned rather rapidly, in some frosty 
conditions, that this car requires a soft touch 
and your utmost respect. The tail-happy 
nature of this car is a big part of its charm 
and the limited slip differential will reel it 
in if you are being a little silly; however, on 
icy or frosty roads, it can quickly become a 
‘squeaky bum’ experience. The 5.0 litre is an 
unbridled piece of old-world magnificence 
as it relentlessly accelerates through every 
millimetre of the rev-range. I didn’t get any-
where close to testing its full capabilities, but 
if you had a track and were brave enough, 
I’m sure this car would perform magnifi-
cently, if you could hang on tight enough.  
The interior of the Mustang is a little cheap 
in places but all-in-all, I found it to be grand; 
the RECARO seats were wonderful and it is 
very spacious. The smorgasbord of track-
derived settings, such as the g-meter, accel-
eration timer, performance shift indicator 
and track mode, were a hoot, not to mention 
the famous ‘line lock’, which locks the front 
Fit for a 
McQueen 
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wheels and allows you to smoke the rear 
tyres in preparation for a drag race. The car 
also has exhaust mode, which you can use 
to quieten or exaggerate your V8 bellow and 
control the V8 ‘blip’ the car makes when you 
shift down the gears. This, paired with the 
impressive Bang and Qlufsen sound system, 
with boot-mounted subwoofer, makes the 
Bullitt its own travelling orchestra.  
Thanks to wonders of modern engineer-
ing, the Bullitt stops quite well despite its 
weight and power, thanks to its Brembo 
brake set-up. It also boasts safety features 
like Pre-Collision Assist with Pedestrian 
Detection (Automatic Emergency Braking 
& Forward Collision Warning), Adaptive 
Cruise Control and Lane Departure Warn-
ing. The model I tested also had the Mag-
neRide Suspension Damping 
System at an additional cost of 
€3,030. 
In 2018, I tested its smaller sibling, the 
2.3-litre Ecoboost (turbo) and I noticed that 
Irish people loved the Mustang, a point that 
was exaggerated in the louder and more 
brutish Bullitt. The general public couldn’t 
get enough of this car, happy faces, waves 
and smiles that you wouldn’t see from the 
driver’s seat of an ice-cream van. In a pre-
vious review, I likened the Ford Fiesta ST3 
to a Jack Russell terrier, “small and feisty, 
with the guts to back it up”. Well, the Bullitt 
is more like riding around on a disgruntled 
Rottweiler; it looks very cool and it is very 
powerful; however you are always acutely 
aware that it might eat you. Personally, de-
spite the lack of impressive 
engine note, I preferred the €55,500, 317hp, 
2.3 litre Ecoboost, both for its handling, 
which I found to be sharper and overall 
practicality, as I feel the cost of running the 
450hp, 5.0-litre V8 and paying the €2,350 
road tax to cover its 277g/km emissions may 
become a little tedious.  
The Bullitt starts at €73,092, however the 
model I tested cost €78,842. You get a lot of 
power for that money and I love fast Fords, 
but I must admit, if it was my money I’d go 
for the more practical and less expensive 
Ecoboost, which I adore, and deal with peo-
ple taunting me for being a realist instead of 
a purist. ●
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PRODUCT LAUNCH
Over 100,000 fewer inhalers may be disposed of each year as Boehringer Ingelheim launches Respimat reusable — the first reusable, soft mist inhaler
Boehringer Ingelheim has an-
nounced the launch of the Respimat 
reusable inhaler in Ireland, which 
could lead to over 112,500 fewer in-
halers being disposed of each year. 
The first soft mist, reusable inhaler 
is now available for use with up to 
six refill cartridges, no longer dis-
posed of and replaced each time 
the medication runs out. Respimat 
has always been propellant-free but 
by using the reusable inhaler with 
six refill cartridges (rather than six 
of the previous disposable inhalers 
with one cartridge each), the prod-
uct carbon footprint is reduced by 71 
per cent. Respimat reusable delivers 
the chronic obstructive pulmonary 
disease (COPD) medications tiotro-
pium/olodaterol (Spiolto), olodaterol 
(Striverdi) and tiotropium (Spiriva), 
as well as the asthma medication tio-
tropium (Spiriva).
Asthma and COPD affect over 490,000 
people in Ireland and chronic lower 
respiratory disease, which includes 
COPD and asthma, is the fourth-most 
common cause of death. Nurses and 
pharmacists are likely to see people 
with COPD and asthma more regular-
ly than a GP or specialist, so they play 
a pivotal role in educating patients 
on their medicines and inhaler tech-
nique, whether this is part of routine 
practice or a specialist commissioned 
pharmacy-based inhaler technique 
check service.
Ireland had the third-highest emis-
sion of greenhouse gases per capita 
in the EU in 2017. The HSE’s Sustain-
ability Strategy for Health outlines 
its commitment to reducing carbon 
emissions and delivering low-car-
bon, quality sustainable healthcare. 
A recent study highlighted that the 
carbon footprint of the original, dis-
posable Respimat is approximately 
20 times smaller than that of pressur-
ised metered-dose inhalers (pMDIs)
and the transition to Respimat reus-
able has the potential to reduce this 
by an additional 71 per cent.
Prof Richard Costello, Professor of 
Medicine at the Royal College of Sur-
geons in Ireland, commented: “This 
move to a reusable Respimat inhaler 
is positive for the environment, with 
patients able to reduce the number 
of inhalers used from 12 to two per 
year. As prescribers in respiratory 
medicine, we are aware of the envi-
ronmental impact of medicines, in-
cluding their carbon emissions and 
plastic waste. 
"I welcome developments towards 
more environmentally-friendly op-
tions with a significantly reduced 
product carbon footprint to help sup-
port HSE targets in the Sustainability 
Strategy for Health.”
Dr Tim Crossman, Head of Medi-
cal Affairs, Boehringer Ingelheim 
UK and Ireland, added: “Boehringer 
Ingelheim is committed to sustain-
able healthcare, and we recognise 
the need to reduce plastic waste and 
carbon emissions. We are increas-
ingly conscious of the environmental 
impact of the medicines we develop 
and hope that the introduction of 
this reusable inhaler is seen as a posi-
tive step in reducing the carbon foot-
print of inhalers.”
This inhaler is a reusable version of 
Boehringer Ingelheim’s well-estab-
lished Respimat (disposable) soft 
mist inhaler and was introduced 
following patient and healthcare 
professional feedback. Nurses, phar-
macists and patients will be familiar 
with the day-to-day use of Respimat 
reusable, which remains the same for 
patients; indications for prescribing, 
recommended dose, and the safety 
and efficacy profile of the inhalers 
remain unchanged.
Prescribing and dispensing of Res-
pimat inhalers will change so that 
a patient’s initial prescription pack 
contains one inhaler plus one car-
tridge, followed by packs containing 
just one refill cartridge. 
At six months, the patient will once 
again receive one inhaler plus one 
cartridge. The dose counter has 
been improved — it is larger and 
more clearly shows when the medi-
cation is running low and needs to 
be replaced. The clear base of the 
Respimat reusable inhaler automati-
cally detaches when the cartridge 
is empty as a clear indication to the 
patient of when the cartridge needs 
to be replaced.
Boehringer Ingelheim has created 
dedicated educational websites for 
healthcare professionals and patients 
to find out more about the change 
in order to support the transition to 
Respimat reusable. For more infor-
mation, please visit www.medical.
respimat.com/ie.
APPOINTMENT
Pharmaforce announces appointment of Ms Alison Conroy to Recruitment Specialist as the Pharmed Group expansion continues 
Contract Sales Outsourcing and Re-
cruitment experts Pharmaforce has 
further accelerated its growth plans 
with the appointment of Ms Alison 
Conroy to Recruitment Specialist. 
Ms Conroy joins the Pharmaforce 
team with an extensive business 
background and over eight years’ ex-
perience working across a number 
of industries including healthcare, 
IT, online and gaming, and most 
recently manufacturing and engi-
neering. Ms Conroy has extensive 
experience in delivering on complex 
business resourcing needs, including 
high-volume recruitment campaigns. 
Prior to joining Pharmaforce, she was 
a recruiter with Intel, where she was 
responsible for managing the busi-
ness resourcing needs of high-volume 
recruitment and selection across all 
their divisions. She was also instru-
mental in developing their graduate 
programme and related recruitment 
activities.
Pharmaforce provides a range of con-
tract sales outsourcing and recruit-
ment services to pharmaceutical and 
healthcare companies. It is also the HR 
and recruitment arm of the Pharmed 
Group — an award-winning health-
care and pharmaceutical services 
provider that offers sales, marketing, 
distribution and support services to 
all sectors of the healthcare market 
across Ireland and the UK. Operating 
across three core business units: Medi-
cal and Scientific, Pharmaceutical and 
OTC, and contract outsourcing and re-
cruitment, the Group has experienced 
significant growth recently and now 
employs over 170 people.
Commercial Director of Pharmaforce 
Ms Bethann Doherty said: “We are 
delighted to have Alison join us at a 
time when we have seen substantial 
growth across all areas of the Pharma-
force business, as well as the unprec-
edented growth across the Pharmed 
Group as a whole. I have no doubt that 
she will make a dynamic contribution 
to the team. Alison’s experience of re-
cruitment within the manufacturing 
and engineering sectors will enhance 
this growing area of our business.”
Ms Conroy graduated from Waterford 
Institute of Technology in 2010 with a 
Bachelor of Science in Retail Manage-
ment and from NUI Galway in 2011 
with a Master of Science in Industrial 
Relations and HR Management.
Ms Alison Conroy
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